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ABSTRACT 
 
Laminin-deficient congenital muscular dystrophy 1A (MDC1A) is the second 
most prevalent congenital muscular dystrophy (CMD) and is due to a defect in the alpha 
chain of the basement membrane protein laminin-211. This protein serves as the vital link 
between the muscle cell membrane (sarcolemma) and the extracellular matrix (ECM) via 
interactions with integrins and a-dystroglycan. Loss of laminin results in impaired 
myofiber anchoring, structural instability, and a multitude of dysregulated signaling 
pathways leading to many devastating secondary pathologies. Much of the work to date 
has focused on studying pathology at the end-stages of disease in mouse models. 
However, because this is a congenital disease that presents at/soon after birth, the most 
relevant time periods of study are those that most closely reflect human disease, early 
development. This thesis will characterize dysregulated pathways throughout 
development and into end-stage pathology as well as elucidate amelioration of these 
pathways due to intervention and applicable non-invasive biomeasures to track 
therapeutic progress. Because this work focuses on secondary manifestations of 
pathology, the work outlined in this thesis has the potential to be applied to an array of 
neurodegenerative diseases that are currently without any form of treatment. 
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Chapter 1: Introduction 
 
1.1 Introduction 
 
This thesis will focus on fibrotic pathomechanisms in the DyW mouse model of 
Laminin-deficient congenital muscular dystrophy. Specifically, in this work I will 
elucidate the state of integrin dysregulation, with a particular focus on the role of 
Integrin-〈V, as well as show the prominence of myofibroblast transdifferentiation. 
Because this disease is congenital and pathology begins at or shortly after birth, the 
 
characterization of these pathways will also be elucidated during the development of 
DyW mice to determine if the dysregulation of these interconnected pathomechanisms 
could be etiological. Lastly, this thesis will determine if the dysregulation of these 
pathways can be reversed with anti-fibrotic therapies. Determining biological pathways 
relevant to disease progression and their evolution throughout pathology is critical to 
determining effective therapies as well as timelines for implementation. Further, because 
this work is on pathological consequences and not the direct genetic defect, this work can 
be translated to other fibrotic, neurodegenerative diseases that are currently without 
effective therapy. 
1.2 Congenital Muscular Dystrophy: general features 
 
Congenital muscular dystrophies (CMDs) are a clinically and genetically 
heterogeneous group of neuromuscular disorders that present at/near infancy with muscle 
weakness, decreased muscle tone, and dystrophic muscle biopsies (1). Dystrophic 
myopathies can be differentiated from general myopathies in that dystrophies are 
progressively degenerative and result in increased endomysial connective tissue whereas 
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myopathies are generally not progressive or degenerative (2). The historic prevalence of 
CMDs is not quite clear because of the difficulty in making clear-cut diagnoses. It has not 
been until recently, with the advent of new sequencing techniques, that an abundance of 
new insight into these diseases and their specific genetic defects has been identified. 
Nonetheless, estimates of general CMD prevalence range anywhere from 0.6–2.5 per 
100,000 children born (1, 3, 4). 
Diagnoses of CMDs are accomplished with serum creatine kinase (CK) 
concentration assays, muscle/brain MRIs, histological examinations, and genetic testing. 
Typically, CK assays are first done because they are relatively quick and painless, and 
elevated CK levels in the circulation indicate muscle damage—the first alert to a 
muscle—specific problem. MRI findings for CMD patients include the presence of fatty 
infiltrates in the muscle. The most accurate test to determine the presence of a CMD, 
however, is muscle biopsies. Biopsies from CMD patients display abnormal fiber size 
distribution, increases in fatty and fibrotic tissue throughout the affected muscles, and 
some show increases in centrally nucleated fibers (indicative of regeneration). 
Immunohistological examinations of muscle-specific proteins can further help to 
determine the actual diagnosis, however it is often not until genome sequencing that the 
exact diagnosis can be accurately made (1, 5, 6). 
While symptoms of children with CMD can be disease-specific, general 
symptoms include severe muscle weakness, hypotonia (decreased muscle tone), 
congenital joint contractures, hip dislocation, and eye abnormalities including retinal 
dysplasia and congenital cataracts. Due to their severe muscle weakness, these babies are 
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often termed “floppy babies” because of their inability to hold their head up when picked 
up off the floor (Fig. 1.2.1). While some children born with CMD have the ability to walk 
unassisted for a short period of time, most children are wheelchair bound and never 
ambulate independently. Cardiomyopathies are also relatively rare in children with CMD 
but some subtypes develop cardiac abnormalities in the second decade of life. Congenital 
cardiac symptoms are often indicative of a metabolic condition and not CMD. 
Additionally, central nervous system involvement is relatively uncommon, but can be 
present in diseases with mutations in proteins involved in neurogenesis and can result in 
seizures. Besides skeletal muscle deficiencies, respiratory insufficiencies are the other 
major complication attributed to children with CMD. Many children require respirators 
for the night and often succumb to respiratory failure at the terminal stages of their 
disease (6-9). 
1.3 Dystrophin-Glycoprotein Complex and its relation to CMD 
 
Many CMDs, while heterogeneous, are caused by defects in proteins localized in, 
or associated with, the Dystrophin-Glycoprotein Complex (DGC). The DGC is located at 
the muscle cell membrane (sarcolemma) and is composed of many transmembrane 
proteins and their (potentially numerous) intra- and extracellular binding partners (Fig. 
1.3.1). The main components of this complex include dystrophin, which binds the 
dystroglycan complex made up of beta (which dystrophin binds intracellularly) and alpha 
dystroglycan, which binds extracellular proteins like Laminin-211. Other proteins critical 
to this complex include the four sarcoglycans, sarcospan, dysferlin, dystrobrevins, and 
syntrophins. Of these proteins, mutations in laminin-〈2 (Lama2-related CMD), collagen 
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VI (Ulrich and Bethlem CMD) in the muscle ECM, inadequate glycosylation of alpha 
dystroglycan (Fukuyama CMD, muscle-eye-brain disease, Walker-Warburg syndrome, 
Fukutin-related protein CMD, Large-related protein CMD) cause CMD. Of note, 
mutations in Integrin-〈7®1 (which also binds Laminin-211), selenoprotein N and the 
nuclear protein lamin A have also been shown to cause CMD but are not directly 
associated with the DGC (10-12). 
Due to the fact that the DGC connects the sarcolemma to its extracellular 
environment it was classically believed that the DGC provides mechanical stability for 
muscle fibers during contractions. Additionally, due to the localization of DGCs at 
costameres, specialized sub-membrane protein complexes (analogous to focal adhesions) 
that align with the Z-disc of the sarcomeric contractile apparatus and connect it to the 
sarcolemma, it is also thought that the DGC plays a critical role in coupling force 
transmission from the intracellular sarcomere through the sarcolemma and ultimately to 
neighboring muscle cells (Fig. 1.3.2) (13, 14). It can be surmised, then, that loss of any of 
these proteins would lead to decreased force transmission (weakness) and altered 
membrane stability during contractions (though the latter is not always the case). In 
addition to its critical role in membrane stability and force transmission, the DGC also 
plays a critical role in signal transmission from the ECM to the cell. This signaling is 
mainly carried through the muscle basement membrane protein Laminin-211 via its 
connections with alpha-dystroglycan and 〈7®1 integrin (11, 12). 
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1.4 Laminin-〈2: general features, localization, roles 
 
Laminins are large (400–900 kDa) heterotrimeric proteins made of one alpha, one 
beta, and one gamma subunit that come together to form a T-shaped protein. To date, five 
〈, three ®, and three © chains have been identified which can form 15 distinct Laminin 
isoforms that are named for the different combinations of alpha, beta, gamma chains that 
make up the trimer. These isoforms are localized at the basement membrane and 
expressed in a tissue-specific manner (15-17). It is well established that Laminin-211 
(originally called merosin), made of the alpha 2, beta 1, and gamma 1 chains, is the 
dominant Laminin isoform in skeletal muscle (18). Disruption in the LAMA2 gene that 
encodes for the alpha 2 chain causes Lama2-related CMD (1, 8, 9, 19-23). 
The LAMA2 gene is located on chromosome 6q22-23 in humans and 
chromosome 10 in mice. The gene is composed of 65 exons with a predicted molecular 
weight of 390 kDa. The protein is however cleaved into an N-terminal 300 kDa fragment 
and an 80 kDa C-terminal fragment that remain non-covalently associated with each  
other (20-22). The full-length alpha 2 chain is composed of multiple globular and rod-like 
domains (Fig. 1.4.1). It is composed of N-terminal globular domains LN, L4a and L4b 
that are separated by LEa,b,c (epidermal growth factor-like repeats) rod-like spacers 
followed by a laminin coiled coil (LCC) of all three chains and finally terminating in five 
C-terminal globular domains (LG1-5) (15). Each of these domains has been ascribed 
distinct biological activity. The N-terminal LN domain is critical for the ability of 
Laminin-211 to polymerize and associate into the basement membrane (16). Mutations of 
this domain decrease polymer association and subsequent completion and proper 
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basement membrane formation (24). This domain also supports associations with other 
ECM proteins like the sulfated glycoprotein nidogen and the heparan sulfate 
proteoglycans agrin and perlecan (25). The coiled-coil domain is responsible for 
assembly of specific heterotrimers (Laminin-〈2 can assemble to form other Laminin 
heterotrimers distinct from -211) (16). The LG domains at the C-terminal are responsible 
for binding to cell-surface receptors, namely 〈-dystroglycan and 〈7®1 integrin (Fig. 
1.4.2) (26, 27). Specifically, the LG4-5 domains bind the glycosylated regions of alpha- 
dystroglycan. This interaction is critical for myofiber attachment to the basement 
membrane. Loss of this interaction results in anchorage-dependent apoptosis (anoikis) 
(26). Laminin-211 binds 〈7®1 integrin via the LG2-3 domains (25). These interactions 
help connect Laminin-211, and by association the extracellular environment, to the 
intracellular cytoskeleton for critical signal transduction across the sarcolemma. 
1.5 Laminin expression during myogenesis 
 
The first Laminin alpha chain expressed in developing muscle is Laminin-〈1, 
which guides initial myotube formation (primary myogenesis). Laminin-〈2 is first 
expressed in skeletal muscle basement membrane following primary myogenesis on day 
E11 in mice, therefore replacing Laminin-〈1, which at this point is restricted to the ends 
of myofibers near myotendinous junctions (28). Interestingly, mutations in Laminin-〈2 
do not induce deleterious molecular defects in early myogenesis but patients with 
MDC1A do show smaller myofibers than healthy babies (21, 22, 29). 
The 〈2 chain, however, is absolutely critical to the normal ECM meshwork that 
 
forms the muscle, muscle tendon junction as well as the neuromuscular junction and 
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myelinating Schwann cell basement membranes in adult muscles (28). Proper function of 
this protein is vital in the stabilization/maintenance of these structures in differentiated 
skeletal muscle and defects in this protein lead to the devastating neuromuscular disease 
Lama2-related congenital muscular dystrophy. 
1.6 Lama2-related congenital muscular dystrophy (MDC1A) 
 
Lama2-releated congenital muscular dystrophy (also known as Merosin-deficient 
congenital muscular dystrophy; MDC1A) is an autosomal recessive neuromuscular 
disease first designated in 1994 by Tome et. al who described a form of congenital onset 
dystrophy accompanied by a loss of the Laminin-〈2 chain (30). The rate of incidence of 
MDC1A is estimated at approximately 7 x 10-6 but accounts for almost 40% of CMD in 
 
Europe and is the second most prevalent CMD in the United States behind Collagen-VI 
deficiency, with a prevalence of 0.9/100,000 children (31, 32). Approximately 55% of the 
mutations have been localized to exons 14, 25, 26, and 27, that result in total loss of 
Laminin-〈2 expression are stop mutations and lead to the most severe MDC1A 
phenotypes. There is also a correlation between the amount of Laminin-211 expressed in 
the basement membrane and the severity of the disease. Patients with less Laminin 
expression are more likely to show symptoms earlier, have less ambulatory capability (if 
any), and need feeding and respiratory support earlier than those with some residual 
Laminin expression (33). Conversely, in-frame mutations that affect the G domains of the 
protein, previously noted to be critical for cell surface protein binding, can also lead to 
quite severe phenotypes even though the protein may still be localized to the basement 
membrane as seen by immunohistochemical staining. Compound heterozygosity for a 
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null mutation or an in-frame or exon-skipping deletions have also been shown to cause 
milder forms of MDC1A (32-36). 
Patients with MDC1A present at or soon after birth with severe muscle hypotonia 
and general muscle weakness accompanied by joint contractures most often at the 
elbows, ankles, hips, and knees along with kyphosis and scoliosis, severely delayed 
motor milestones and most often a complete lack of independent ambulation. These 
children also face feeding and breathing difficulties and often require the use of enteral 
and ventilator support to improve their health (1, 32). Because Laminin-〈2 is also 
expressed in Schwann cells in the peripheral nervous system and to some extent in the 
central nervous system and heart, patients with MDC1A can also be faced with nervous 
and circulatory system issues including nerve conduction deficiencies, white matter 
abnormalities, seizures, and left ventricular dysfunction (1, 18, 37, 38). MDC1A is 
terminal around the second decade of life with respiratory insufficiency/infection and 
failure to thrive as the main drivers of morbidity and mortality (32). Currently, there are 
no therapies of any kind, with the exception of palliative care, available to these children. 
1.7 MDC1A mouse models 
 
There are multiple mouse models for MDC1A, each of which have varying 
degrees of Laminin expression and therefore, like the human disease, varying degrees of 
severity. The dy/dy mouse harbors a spontaneous mutation (though the causative 
mutation has yet to be identified) that results in decreased expression of the Laminin-〈2 
chain. These mice have a somewhat reduced life span (~6 months) and exhibit a 
moderate form of muscular dystrophy and peripheral neuropathy (21, 23). The dy2j 
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mouse harbors a mutation in the N-terminal (LN) domain resulting in splicing defects and 
slightly reduced Laminin expression. These mice have relatively normal lifespans but 
experience a mild muscular dystrophy and peripheral neuropathy (39, 40). Two other 
mouse models have been engineered with increasing degrees of severity. The dy3k mouse 
is completely devoid of any Laminin-〈2 expression and therefore presents with a disease 
that is likely even more severe than the clinical progression of MDC1A. These mice 
exhibit a severe muscular dystrophy and peripheral neuropathy, leading to a significantly 
shortened lifespan of about 4 weeks (41-43). The dyw (DyW) mouse harbors a mutation 
that results in the expression of a truncated Laminin-〈2 completely devoid of the LN 
domain resulting in very minimal Laminin-211 expression in the basement membrane. 
DyW mice have shortened lifespans in the range of 10–15 weeks (depending on the 
reporting lab) and present with severe muscular dystrophy as well as peripheral 
neuropathy (41, 44). Of these, the DyW mouse is regarded as the mouse model most 
closely recapitulating the general severity and disease progression of human MDC1A 
patients and will be discussed as the mouse model of choice for purpose of this thesis. 
1.8 Pathomechanisms of MDC1A: prominence of fibrosis 
 
While the genetic defects of MDC1A pathology are well known, the driving 
forces of the devastating secondary manifestations of the disease are yet to be fully 
understood. Even though Laminin is essential for connecting the muscle fiber to the 
extracellular matrix (ECM), the sarcolemma in Lama2-deficient muscle fibers does not 
exhibit increased susceptibility to mechanical damage as demonstrated by a lack of Evans 
Blue Dye uptake in these fibers (45). Loss of Lama2 does however result in alterations in 
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the expression pattern in other Laminin chains. Lama2-deficient muscles show 
significantly reduced expression of the Laminin-®2 chain (46) and significantly 
increased expression of the Laminin-〈4 and –〈5 chains (28, 47), potentially as a 
compensatory mechanism for the loss of Laminin-〈2 though they do not seem to be able 
to compensate well enough as there is still considerable dystrophic pathology in affected 
muscles. 
Lama2-deficient muscles also show secondary reduction of cell surface proteins that 
normally associate with Laminin. Specifically, there is significant reduction in 
Integrin- 〈7®1 (48) which potentially abolishes critical signaling downstream of this 
protein. 
Reductions in 〈-dystroglycan have also been reported (49). These results raise the 
possibility that Laminin expression may be critical in guiding the localization and 
stabilization of proper protein localization at the sarcolemma. There is also significant 
signaling dysregulation in Laminin-deficiency that leads to significant fiber size 
variations including a much larger proportion of smaller fibers, increases in centrally 
nucleated i.e. regenerating fibers, a massive abundance of infiltrating cells, extensive 
endomysial fibrosis, apoptosis and necrosis (6, 35, 50-53). Of these, the early onset and 
severity of fibrosis remains a unique and devastating consequence of primary Laminin- 
〈2 deficiency. 
In a normal regenerative process, for example after acute tissue injury, resident 
and newly infiltrating inflammatory cells, primarily neutrophils and macrophages, 
phagocytose the cellular debris and degenerating muscle fibers. They also secrete soluble 
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growth factors to instruct resident fibroblasts to secrete a transient new matrix in order to 
promote muscle stem cells (satellite cells) to proliferate, differentiate, and fuse with the 
existing muscle to repair the damage and return the tissue to homeostasis (54, 55). In a 
pathological scenario where regeneration fails, such as in MDC1A, this process becomes 
constitutive and the connective tissue deposition becomes excessive and uncontrolled. 
This scar tissue formation, or fibrosis, can have devastating effects on normal tissue 
physiology (56). 
1.9 TGF-® signaling pathway 
 
The major pathway involved in promoting fibrosis in most diseases, including 
muscular dystrophies, is the Transforming Growth Factor-beta (TGF-®) pathway (56-
58). This pro-fibrotic cytokine is synthesized as a precursor protein in the endoplasmic 
reticulum and assembled as a non-covalently bound complex of a short C-terminal 
disulfide linked homodimer (the mature cytokine) and a longer N-terminal disulfide 
linked homodimer that is known as the Latency Associated Peptide (LAP). This 
complex is known as the small latent complex (SLC). The SLC is further non-covalently 
linked to another set of proteins in the ER called latent TGF-® binding proteins (LTBPs) 
to form the large latent complex (LLC). The LLC is secreted from cells and the LTBPs 
are tethered to the ECM (Fig. 1.9.1). This latent complex keeps the TGF-beta receptor 
binding domains hidden and thus the cytokine remains inactive when in this complex 
(59). Much of TGF-® regulation is achieved at this level. 
When TGF-® is activated/released from this complex, which can occur passively 
due to changes in pH or temperature or actively via mechanical or proteolytic cleavage 
of the mature TGF-® peptide from the complex (59), the ligand then binds freely to 
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TGF-® receptors 1 and 2 (TGFBR1, TGFBR2). Once bound, the two receptors dimerize 
and the kinase of TGFBR2 phosphorylates TGFBR1 to initiate the Smad signaling 
cascade downstream of TGF-®. Briefly, Smad2/3 proteins, anchored to the TGFBR1 
become phosphorylated freeing them from receptor binding, dimerize, and bind with the 
co- smad4. Once the smad2/3-smad4 complex is complete, conformational changes 
expose the nuclear localization sequence allowing the complex to enter the nucleus. 
These transcriptions factors then work with specific co-factors to initiate transcription of 
TGF- ®-responsive genes including ECM proteins, matricellular (non-structural ECM 
proteins) proteins, matrix metalloprotease (MMP) inhibitors called TIMPs (tissue 
inhibitors of metalloproteases) and TGF-® itself (57-61). When left unchecked, TGF-
® signaling can become cyclical and cause the continuing deposition of fibrotic material 
in the damaged tissue. 
1.10 Role of integrins in TGF-® signaling 
 
One of the ways in which TGF-® can become activated/freed from its latent 
complex is through the actions of integrins. Integrins comprise a family of 18 alpha and 
8 beta proteins that come together to form 24 distinct heterodimeric, membrane-spanning 
proteins made of one 〈 and one ® subunit where the alpha subunit imparts ligand 
specificity and the ® subunit is the effector of downstream signaling. These proteins 
often serve as receptors for laminins and other extra/matricellular proteins and participate 
in a wide array of cellular functions including migration, signal transduction and cell 
stability. In particular, Integrin-〈V, along with its beta dimer partners -®1, -®3, -®5, -
®6, and -®8, has been shown to be intricately linked to TGF-® signaling dysregulation 
in the progression of many diseases including cancer, heart disease, and the fibrosis of 
16 	
various organs (62-65). 
 
Integrin-〈V, when in complex with its aforementioned beta dimer partners can 
release TGF-® by binding to the arginine-glycine-aspartic acid (RGD) domain of the 
LAP, either by inducing adhesion-mediated conformational changes or bringing matrix 
metalloproteinases (MMPs) into physical contact with the complex leading to enzymatic 
release (Fig. 1.10.1). This interaction is so critical that mouse models with a mutated 
RGD motif on LAP have similar phenotypes to TGF-®1 and TGF-®3 knockout mice 
(19, 62-70). 
1.11 Role of integrins in myofibroblast transdifferentiation 
 
During chronically dysregulated TGF-® signaling, cooperation between Integrin- 
〈V and TGF-® has been shown to induce myofibroblastic transdifferentiation in a 
number of cell types. Myofibroblasts are contractile, hyper-secretory fibroblastic cells 
that are activated following tissue injury and are part of the normal wound healing 
process. Their secretions and contractile properties are critical to facilitate migration of 
inflammatory and tissue stem cells to the site of injury as well as induce wound closure. 
Normally, following the conclusion of regeneration they undergo mass apoptosis due to 
the decreased matrix stiffness or de-differentiate back to their original cell types. 
However, in pathological scenarios, these cells can persist and significantly exacerbate 
fibrotic pathology (66, 71-78). 
Multiple cell types become myofibroblasts via TGF-® signaling, which induces 
the expression of epithelial to mesenchymal transdifferentiation (EMT) related 
transcription factors (Slug, Snail, Twist). These proteins then facilitate changes in gene 
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expression and in the integrin repertoire to facilitate myofibroblast transdifferentiation 
(MT) (79). These changes also alter the extracellular milieu, including increases in 
matricellular proteins, fibronectin splice variants, and matrix tension, all of which drive 
Integrin-〈V-mediated myofibroblast transdifferentiation (Fig. 1.11.1) (74, 76, 77). 
Myofibroblasts are also known to be hyperproliferative and deposit more ECM material 
 
compared to inactivated tissue-resident fibroblasts. Finally, the increased contractility 
typically associated with myofibroblasts (because of the induction of 〈-smooth muscle 
actin stress fibers) can increase ECM stiffness which is not only inherently detrimental to 
normal muscle function, but also can be a positive regulator of Integrin-TGF-
® interactions thus creating a feed-forward loop driving matrix remodeling and 
myofibrogenesis (71, 75, 80-85). 
As previously stated, there are multiple different cell types that have been shown 
to transdifferentiate to myofibroblasts. While fibroblasts are the most prominent cell type, 
hepatic stellate cells, smooth muscle cells, and bone marrow derived progenitors like 
pericytes and fibrocytes have also been shown to undergo this transition under the right 
conditions (Fig. 1.11.2) (74, 76). Interestingly, myoblasts are also capable of 
transdifferentiating to myofibroblasts (86, 87). It has been shown that C2C12 myoblasts 
can undergo transdifferentiation to myofibroblasts in a TGF-®, S1P3 (Sphingosine-1 
phosphate receptor 3), Rho/Rho kinase (ROCK)-dependent pathway (86). This too 
converges on Integrin-〈V as it has also been shown that S1P can activate Integrin-〈V, 
through ROCK, to bind and release TGF-® from its latent complex (68). 
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1.12 Conclusion 
 
Despite extensive research into the secondary manifestations of Laminin- 
deficiency, much remains to be elucidated into the specific pathomechanisms that drive 
the severity of MDC1A. Additionally, whereas most studies to date have focused on  
older mice, given that MDC1A is a congenital disease it is imperative to begin these 
studies as early in development as possible to understand how the disease evolves in  
order to best generate an effective therapy. The present study characterizes major fibrotic 
signaling pathways that contribute to MDC1A pathology early in development in an 
effort to identify key players in pathology, elucidate biomarkers, and determine effective 
anti-fibrotic therapies to attenuate their dysregulation. This work presents a novel focus 
on underlying mechanisms that drive fibrosis in muscular dystrophy. Additionally, while 
integrins are well known to be major drivers of pathology in other diseases like cancer, 
heart disease, and the fibroses of various organs, their role in muscular dystrophy is 
largely unknown and therefore results from this study bring a novel concept to the 
muscular dystrophy field. Myofibroblastic differentiation is also a novel contribution to 
the understanding of the pathophysiology of muscular dystrophy. 
In the same vein, because Integrin-〈V is a convergence point for both TGF-
® mediated fibrosis and MT, the inhibition of –〈V signaling provides an ideal 
therapeutic target for resolution of these pathological processes. The following study 
therefore offers an experimental design that comprehensively characterizes the roles of 
two prominent, parallel and interdependent processes (MT and integrin dysregulation) in 
the induction and mediation of MDC1A pathology as well as a therapy to resolve them. 
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Further, because of similar secondary pathologies, the results of this study could provide 
a potential therapy and/or therapeutic targets for not only MDC1A, but also a whole 
array of other fibrotic, neurodegenerative diseases. 
 
 
 
 
Fig. 1.2.1-Phenotypical manifestations of CMD. Patient with CMD presents with 
typical clinical manifestations of the disease including facial weakness and elbow 
contractures (A), knee contractures and lumbar hyperlordosis (B), as well as trunk, hip, 
and head weakness when picked up from lying position. Taken from Gawlik and Durbeej, 
2011. 
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Fig. 1.3.1-Connections of Laminin-211 at the sarcolemma. Laminin-211 (arrows) is 
bound to both 〈-dystroglycan and 〈7®1 integrin. Because of its localization and 
connections to both cell and matrix it plays a fundamental role in signaling. Adapted from 
http://neuromuscular.wustl.edu/musdist/dag2.htm 
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Fig. 1.3.2-Costameric proteins anchor the sarcolemma and help transduce force. 
Protein complexes that align at the Z disc (blue arrow), mainly the DGC and associated 
proteins, couple the contractile apparatus to the extracellular matrix and play critical roles 
in force transmission. Of these, laminin-211 (green arrows) is the main connection point 
between muscle and matrix. Adapted from Hughes, Wallace, and Baar, 2015. 
22 	
 
 
 
 
 
Fig. 1.4.1-Laminin-211 heterotrimeric structure. The structure of Laminin-211 can be 
see above. The 〈2 chain can be seen in red, ®1 chain in green, and ©1 in blue. The N- 
terminal domains of laminin-〈2 consist of the N-terminal globular domain (LN), tandem 
rod domains of EGF repeats (LEa,b,c) which separate the LN from the L4a and L4b 
globular domains. The laminin coiled coil (LCC) domain consists of all three chains 
interwound that leads to the C-terminal globular domains (LG1-5). Taken from Gawlik 
and Durbeej, 2011. 
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Fig. 1.4.2-Laminin-211 globular domain binding partners. Laminin-211 binds to 
Integrin-〈7®1 (A) as well as the glycosylated regions of 〈-dystroglycan (B) via its C- 
terminal globular domains. Adapted from Gawlik and Durbeej, 2011. 
A	 B	
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Fig. 1.9.1-TGF-® synthesis and secretion. TGF-® is transcribed as a precursor that 
dimerizes and is cleaved to become a homodimer. This structure is known as the small 
latent complex (SLC). The SLC is further non-covalently bound to latent TGF-® binding 
proteins (LTBPs) to form the large latent complex (LLC) which is then secreted into the 
cytosol where it becomes tethered to the ECM close to its cell surface receptors. Taken 
from Hayashi and Sakai, 2012. 
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Fig. 1.10.1-TGF-® activation by Integrin-〈V integrins. Upon activation by 
matricellular proteins containing RGD sequences (blue shapes with red lines in figure), 
Integrin-〈V becomes activated to bind and activate TGF-® from the latent complex by 
binding the RGD sequence on the LAP. Once activated, TGF-® is then freely able to 
bind its cell surface receptor and initiate smad signaling. Adapted from Patsenker and 
Stickel, 2011. 
OPN	
 PN	 FN	
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Fig. 1.11.1-Cyclical role of Integrin-〈V in myofibroblast transdifferentiation. 
Integrin-〈V has the capability of activating TGF-® from its latent complex in the ECM 
which initiates downstream signaling. This downstream signaling increases gene 
expression of multiple TGF-®-responsive genes including proteins responsible for 
increasing matrix stiffness and Integrin-〈V itself. These feed into inducing myofibroblast 
transdifferentiation. The increased matrix stiffness also increases Integrin-〈V-TGF-
® interactions thus acting as a feed forward mechanism toward exacerbating fibrotic 
pathology. Adapted from Mamuya and Duncan, 2012. 
snail	 slug	 twist	
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Fig. 1.11.2-Transdifferentiation to myofibroblasts in multiple cell types. Under the 
right conditions, there are a multitude of different cell types that can contribute to 
myofibrogenesis. This includes satellite cells and myoblasts. Adapted from Forte et al. 
2010. 
?	
Satellite	cell/myoblast	
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Chapter 2: Early DyW pathology is characterized by fibrosis and matricellular 
protein dysregulation 
(N.B. this work appears in: Mehuron, T., Kumar, A., Duarte, L., Yamauchi, J., Accorsi, 
 
A. and Girgenrath, M. (2014) Dysregulation of matricellular proteins is an early signature 
of pathology in laminin-deficient muscular dystrophy. Skelet Muscle, 4, 14.) 
2.1 Introduction 
 
Perhaps the greatest gap in our understanding regarding dystrophic diseases, like 
MDC1A, that take hold so early in life are the major pathomechanisms apparent during 
early disease progression. Because this disease is an aggressive, multifaceted, 
evolutionary disease it is absolutely critical to discern major pathomechanisms at early 
time points in order to elucidate effective means of therapy and therapeutic 
implementation. At this point, most of the research done on MDC1A pathology comes 
from adult mice and a few from earlier time points in humans and mice. None, however, 
have elucidated molecular mechanisms of disease progression from these early time 
points. While there have been multiple therapeutic interventions utilized in laminin- 
deficient mice, most research rationale was extracted from results conducted in 
dystrophin-deficient, mdx mice. While similar, the two diseases come from vastly 
different defects with dystrophin being an intracellular protein and laminin being 
extracellular and should be treated as such when attempting to understand their complex 
etiologies. Thus, this study sought to determine the relevant signaling pathways that 
contribute to the gross, phenotypical deficiencies of DyW mice, and potentially 
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translatable to humans, including stunted growth, inadequate regenerative potential, and 
early surges of inflammation and fibrosis. 
2.2 Fibrotic tissue buildup is apparent as early as two weeks postnatal 
 
Qualitative assessment of fibrosis using picrosirius red staining, a method used to 
detect the abundance of connective tissue (mainly collagen), we found that there is a build 
up of endomysial connective tissue in DyW mice evident as early as postnatal week     
two that continues throughout week four postnatal (Fig. 2.2.1). This was further supported 
by gene expression of pooled hind limb muscle tissue using qRT-PCR that             
showed Collagen 1a mRNA transcripts are upregulated in DyW mice compared with age- 
matched WT mice (Fig. 2.2.1). This was also quantitated on the protein level with 
hydroxyproline assay. Because hydroxyproline is a major constituent of the protein’s 
backbone and is largely restricted to collagen, measuring levels of hydroxyproline is an 
accurate method of assessing levels of collagen in tissue. We found, similar to picrosirius 
red staining, that by two weeks of age DyW mice had significantly higher amounts of 
hydroxyproline (and therefore collagen) per milligram of muscle tissue than age-matched 
WT littermates. Hydroxyproline remained significantly elevated through postnatal week 
four (Fig. 2.2.1). 
2.3 TGF-® signaling is dysregulated as early as week one postnatal 
 
Because TGF-® is known to be a major driver of fibrosis in many diseases, 
including dystrophy, we next examined the state of TGF-® signaling as well as levels of 
downstream TGF-®-responsive genes. Western blot analyses of smad protein signaling 
showed that there was no change in the amount of total smad2/3 (the smad proteins 
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downstream of TGF-®) between DyW mice and age-matched WT mice while the 
amounts of phosphorylated smad2/3 were significantly greater in DyW mice compared to 
their WT littermates beginning at postnatal week one (Fig. 2.3.1). Additionally, there is a 
significant decrease in the expression of the regulatory smad7 protein, known to be 
inhibitory to TGF-®-induced smad signaling (Fig. 2.3.1). Taken together, this suggests 
that there is a considerably greater amount of TGF-® signaling beginning very early 
during disease progression. 
2.4 Extra/matricellular proteins are significantly dysregulated as early as week one 
postnatal 
There was also a significant increase in many TGF-®-responsive genes including 
structural and nonstructural extracellular matrix proteins (matricellular proteins) as well 
as matrix remodeling proteins like MMPs and their inhibitors TIMPs. In addition to 
Col1a mRNA (as stated above), we also found that the matricellular proteins osteopontin, 
periostin, and fibronectin, proteins that are known to be downstream of TGF-® signaling 
were also significantly upregulated in DyW mice at all time points compared to age- 
matched WT littermates (Fig. 2.4.1). Fibronectin expression was also verified on the 
protein level via immunohistochemical staining (Fig. 2.4.2). Beginning at week one 
postnatal, there is a vastly increased amount of fibronectin staining in DyW muscle 
compared to age-matched WT that persists throughout development. Quantification of 
this staining substantiates the visual observation of increased fibronectin staining 
intensity throughout all four weeks of development in DyW mice, though the difference 
decreases throughout development. Based on the small differences seen in the amount of 
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collagen staining and protein levels, it’s possible that the majority of fibrotic tissue build 
up in DyW muscle is made mainly of fibronectin, rather than collagen. In addition to 
matrix proteins, we also saw upregulation of matrix remodeling enzymes including a 
significant upregulation of MMP2 and MMP9 but an even greater upregulation of their 
inhibitor TIMP1 suggesting that the upregulation of the MMPs may be countered by the 
increased TIMP expression. 
2.5 Discussion 
 
In contrast to diseases like Duchenne Muscular Dystrophy where fibrosis does not 
set in until later, this study shows that fibrosis is an early hallmark of MDC1A-like 
pathology. While we did not see an overt phenotype in DyW mice during the first two 
postnatal weeks, it was clear the underlying molecular mechanisms that produce the 
severe phenotypical abnormalities later in life were activated as early as week one 
including TGF-® signaling dysregulation and matricellular protein dysregulation leading 
to a significant buildup of fibrotic tissue in the endomysium. 
Increases in TGF-® signaling are not only known to promote fibrosis but are 
also detrimental to muscle regeneration. It has been shown that excessive TGF-
® signaling during times of regeneration by injection of recombinant TGF-®1 (88), 
conditional expression (89), or in dystrophic scenarios (56) causes muscular atrophy and 
decreased myogenesis. This could occur potentially through decreased satellite cell 
activation (90) or inhibition of myoblast differentiation through the suppression of 
myogenic transcription factors (91), though we did not see a decrease in the expression 
of these proteins in developing DyW mice (51). 
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We also found significant dysregulation of matricellular proteins including 
fibronectin, osteopontin, and periostin as well as MMP2, MMP9, and TIMP1. These 
proteins not only promote and exacerbate fibrosis, but can also negatively impact satellite 
cell (SC) differentiation due to their negative effects on the myomatrix and tissue rigidity. 
For instance, it has been shown that myoblasts express less myogenin and exhibit lower 
fusion capacity when plated on a surface of only collagen I (92). Additionally, while a 
transient increase in fibronectin (FN) is necessary for SC differentiation, chronically 
elevated FN has been shown to inhibit myogenic differentiation (93). Likewise, while a 
surge of osteopontin expression is necessary in normal muscle regeneration (94), 
chronically high expression of OPN results in increased inflammatory cell infiltration, a 
stiffened matrix, and augmented fibrosis (95). Periostin also negatively affects ECM 
remodeling leading to blunted muscle regeneration (96, 97). Lastly, we found the 
collagenases MMP2 and MMP9 as well as their inhibitor TIMP1 were all significantly 
elevated, TIMP1 more so than either protease. It is possible that this regulation could be 
due in response to the increased fibrosis and increased need for turnover of collagen and 
fibronectin with a negative feedback loop increasing TIMP1; or the MMPs could be 
upregulated due to decreased MMP activity due to the high expression of TIMP1. Further 
experimentation would be needed to determine which is the case. 
In order to properly treat a complex and multifaceted disease the 
pathomechanisms need to be studied longitudinally in order to garner a more full 
understanding of pathology progression. The results of this study show an underlying 
molecular signature that is apparent in DyW mice before gross phenotypical 
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abnormalities take hold. This knowledge is extremely significant and essential to serve as 
a guiding tool for future research on identifying meaningful therapeutic targets and their 
appropriate therapeutic windows. It is apparent that applying an anti-fibrotic therapy 
at/before two weeks of age may be most effective in preserving muscle function and 
potentially muscle size. Future studies will need to be designed to determine if that 
therapy, once implemented, is needed for the lifetime of the patient, or just needed to 
combat these early surges from becoming uncontrolled, secondary disease drivers. 
2.6 Materials and methods 
 
2.6.1 Animal breeding and care 
 
All animals were housed at the Laboratory Animal Care Facility – Charles River Campus 
(LACF-CRC) of Boston University on a 12:12-hr light-dark cycle. Food and water were 
provided ad libitum. All procedures were performed in accordance to the protocol 
approved by the IACUC of Boston University (protocol number 13-055). Heterozygous 
B6.129 Lama2dy-W/+ mice, carrying a targeted mutation in the Lama2 gene, were kindly 
provided by Dr. Eva Engvall (Burnham Institute, La Jolla, CA, USA). Genotyping was 
done by PCR assays on tail snips using the REDExtract-N-AmpTM kit (Simga Aldrich, St. 
Louis, MO) and mice homozygous for the mutation were used as the study animals 
(annotated DyW throughout). 
2.6.2 Muscle tissue collection 
 
Animals were euthanized with isofluorane (Webster Veterinary, Devens, MA, USA) 
before isolating the tibialis anterior (TA), gastrocnemius/soleus complex (GS), and 
quadriceps muscles (QD). Tissues were weighed and snap frozen in liquid nitrogen for 
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RNA and protein extraction. TA/GS muscles used for histology were embedded in 
Tissue-Tek OCT Compound (Sakura Finetek USA, Inc., Torrance, CA, USA) and frozen 
in isopentane (Sigma-Aldrich, St. Louis, MO, USA) chilled in liquid nitrogen. Serial 
transverse sections (7µm) were prepared using the Leica CM 1850 cryostat (Leica 
Microsystems, Inc.) and stored at -80 ̊C (98). 
2.6.3 Histology 
 
For picrosirius red staining, sections were fixed with chilled acetone for 5 minutes and 
then rehydrated through decreasing grades of alcohol. Rehydrated sections were stained 
with Picrosirius red solution for 15 minutes, rinsed twice in 0.5% acetic acid, and then 
dehydrated in increasing grades of alcohol and subsequently cleared in xylene. The 
sections were mounted using Cytoseal 280. 
2.6.4 Immunohistochemistry 
 
Frozen tissue sections were incubated in Acetone for 20 minutes then left to air dry for 15 
minutes. Protocol for Mouse on Mouse (M.O.M.) serial immunostaining for frozen 
sections provided by Vector Labs (Burlingame, CA) was followed using anti-fibronectin 
antibodies (Sigma Aldrich, St. Louis, MO) 1:200 in blocking buffer for 1 hour and 
washed 2x2 in PBS. Sections were then stained with either alexafluor goat anti mouse or 
goat anti rabbit secondary antibodies for 1 hour protected from ligh and washed 3x5 in 
PBS. Finally, Sections were mounted with Vectashield with DAPI (Vector Labs, 
Burlingame, CA) or 2:1 Glycerol:PBS and imaged with a Nikon DSFi1 camera head 
attached to a Nikon ECLIPSE 50i light microscope system. These images were analyzed 
using NIS-Elements Basic Research 3.0 software. 
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2.6.5 Gene expression 
 
RNA from ~25 mg liquid nitrogen snap frozen pooled hind limb muscles was extracted 
with TRIzol reagent (Invitrogen, Carlsbad, CA) according to the manufacturer’s 
instructions. 1µg RNA was reverse-transcribed with the High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems, Foster City, CA, USA). Analysis of gene 
expression was performed with TaqMan assays (Applied Biosystems, Foster City, CA, 
USA) on ABI 7300 Real Time PCR system. 18s ribosomal subunit RNA served as the 
endogenous control and gene expression was calculated by using the ⊗⊗Ct method. 
2.6.6 Hydroxyproline assay 
 
Collagen content in the muscles was determined using a hydroxyproline colorimetric 
assay kit (BioVision Inc., Milpitas, CA, USA) according to the manufacturer’s 
instructions. Briefly, 25 mg of hindlimb muscle tissues from DyW and WT animals were 
pooled and extracted in 500 µl of distilled water. The lysates were acid-hydrolyzed with 
HCl (13 M) at 120°C for 3 hours. Equal amounts of lysates and a series of 
hydroxyproline standards were dispensed in 96-well ELISA plates, evaporated at 60°C 
and oxidized using perchloric acid. The amount of hydroxyproline in samples was 
detected by chromogenic reaction employing chloramine-T and 4- 
dimethylaminobenzaldehyde substrate. The absorbance was read at 560 nm. 
2.6.7 Protein Expression: Western Blot 
 
Muscle tissues (20–25 mg) were homogenized in 20 volumes of passive lysis buffer 
(Promega Bioscience, Inc., San Luis, CA, USA; Cat. No. E1941) containing protease and 
phosphatase inhibitor cocktail (Roche, Indianapolis, IN). Lysate was cleared by 
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centrifugation, and protein concentration was determined using Bio-Rad Protein assay 
(Bio-Rad Laboratories, Hercules, CA, USA). By 10% SDS–PAGE, 20–40 µg of protein 
were resolved and blotted onto a nitrocellulose membrane by semi-dry transfer (Hoefer, 
Inc., Holliston, MA, USA). Blots were blocked with Odyssey blocking buffer diluted 
with TBS (TBST; 50 mM Tris–HCl, 150 mM NaCl, pH 7.6, and 0.1% Tween 20) and 
incubated overnight at 4°C with the following primary antibodies: phosphorylated and 
total Smad2/3 (Cell Signaling Technology, Danvers, MA, USA); Smad7 (R&D Systems, 
Minneapolis, MN, USA) and anti-α-tubulin mouse primary antibodies (Sigma-Aldrich, 
St. Louis, MO) at 4°C overnight. The blot was washed three times for 5 minutes each 
time with TBST (containing 0.1% Tween 20) and subsequently stained with goat anti- 
rabbit IRDye 800CW IgG2b and IRDye 680LT IgG2b antibodies (LI-COR Biosciences, 
Lincoln, NE). Blots were washed as above and scanned on Odyssey Infrared Imaging 
System (LI-COR Biosciences). Densitometric analyses were performed using Odyssey 
Image Analysis software. 
2.6.8 Protein expression: ELISA 
 
Amount of osteopontin was	determined using ELISA kits (Promega, Madison, WI) 
following manufacturer’s instructions. Using lysis buffer containing protease and 
phosphatase inhibitor cocktails, protein was isolated from hind limb and serum samples 
of WT and Dyw mice. The lysates were incubated with the capture antibody for 3 hours 
at room temperature followed by 5 washes with the wash buffer. The wells were washed 
5 times for 3 minutes each and then incubated with detection antibodies for 2 hours at 
room temperature. The wells were then washed as described above and then incubated 
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with Avidin-HRP conjugates. The washing step was repeated again as above and 
incubated with the substrate for 15 minutes. The reactions were stopped subsequently and 
the absorbance was recorded at 450 and 570 nm. 
2.6.9 Statistics 
 
One- and two-way ANOVA as well as student t- tests were performed using GraphPad 
Prism 6 software. Data are presented as mean ± standard deviation. 
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Fig. 2.2.1-Fibrosis is evident as early as two weeks in DyW mice. A) Picrosirius red 
staining on TA muscle sections from DyW and WT mice at postnatal weeks 1–4 shows 
extensive build up of endomysial connective tissue in DyW mice by two weeks. Images 
taken at 20x magnification. Scale bar=100∝m. B) Quantitative assessment of fibrosis 
with hydroxyproline assay shows significant overexpression of collagen at weeks 2–4 in 
DyW mice compared to age-matched WT mice (p<0.05, n=4, two-way ANOVA). C) 
Gene expression measured by qRT-PCR shows significant upregulation of Col1a mRNA 
transcripts at weeks 2 and 4 (p<0.05, n=4, two-way ANOVA). * denotes significance 
between age-matched DyW and WT mice, # denotes significance between DyW mice. 
*=p<0.05; **=p<0.01, ***=p<0.001; ****=p<0.0001. Trend applies to other symbols. 
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Fig. 2.3.1-TGF-® signaling is dysregulated from week one postnatal in DyW mice. 
TGF-® signaling assessed by western blot, shows increased signaling as seen by 
increased phosphorylation of smad2/3 and decreased expression of regulatory smad7 in 
DyW mice compared to age-matched WT mice as early as week one postnatal. 
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Fig. 2.4.1-Matricellular proteins are dysregulated throughout DyW development. A) 
Osteopontin is significantly upregulated (p<0.05, n=4, two-way ANOVA) over age- 
matched WT mice at all time points. B) Osteopontin dysregulation was confirmed via 
ELISA showing it is also significantly overexpressed (p<0.05, n=4, two-way ANOVA) on 
the protein level at all developmental time points. C) Fibronectin and D) Periostin gene 
expression show significant upregulation (p<0.05, n=4, two-way ANOVA) over age- 
matched WT mice at all time points. E) MMP2 and F) MMP9 show inverse relationship 
in expression as MMP2 is not upregulated at week 1 postnatal but is upregulated (p<0.05, 
n=4, two-way ANOVA) at weeks 2-4 while MMP9 is upregulated (p<0.05, n=4, two-way 
ANOVA) at weeks 1-3 but not at week 4. G) TIMP1 is significantly upregulated (p<0.05, 
n=4, two-way ANOVA) at all developmental time points increasing in expression each 
week. * denotes significance between age-matched DyW and WT mice; # denotes 
significance in the DyW groups; Δ denotes significance in the WT groups. *=p<0.05; 
**=p<0.01, ***=p<0.001; ****=p<0.0001. Trend applies to other symbols. 
A	 B	
C	 D	
E	 F	 G	
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Fig. 2.4.2-Fibronectin makes up much of the interstitial connective tissue in DyW 
mice. A) Fibronectin-1 immunostaining with anti-FN1 antibody shows overexpression of 
fibronectin at all time points. Coupling this result with the small increases in collagen 
suggests fibronectin is the main constituent of DyW fibrotic tissue. B) Quantification of 
fibronectin staining using fluorescence threshold shows significant overexpression 
(p<0.05, n=3, t-test) of fibronectin in DyW mice compared to age-matched WT at all time 
points. 
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Chapter 3: Integrin-〈V provides a convergence point between TGF-® signaling and 
matricellular protein expression 
(N.B. this work appears in Accorsi, A., Mehuron, T., Kumar, A., Rhee, Y. and 
Girgenrath, M. (2015) Integrin dysregulation as a possible driver of matrix remodeling in 
Laminin-deficient congenital muscular dystrophy (MDC1A). Journal of Neuromuscular 
Diseases, 2, 51–61. The final publication is available at IOS Press through http://dx.doi.org/DOI:10.3233/JND-140042 ). 
3.1 Introduction 
 
The most outstanding finding of our initial early characterization was the early 
onset and extent of fibrosis and matricellular protein dysregulation seen during the 
development of DyW pathology. We next looked for a link between the TGF-® signaling 
pathway and matricellular proteins, besides the fact that matricellular protein expression 
is downstream of TGF-®. Literature review continually showed that integrin-〈V is a vital 
convergence point in that that matricellular proteins osteopontin, periostin, and 
fibronectin (specifically the splice variant ED-A) contain RGD domains that are ligands 
for integrin-〈V to activate TGF-® (63-65, 99). As previously described, the activated 
form of integrin-〈V can bind the LAP of the LLC and facilitate the release of TGF-® to 
initiate TGF-® signaling. TGF-® signaling then induces the upregulation of the 
aforementioned matricellular proteins as well as integrin-〈V thereby potentiating a self- 
amplifying loop exacerbating fibrotic pathology. Since integrin-〈V drives fibrosis in 
diseases like cancer, heart disease, and other organ fibroses (kidney, liver, lung, skin) we 
sought to determine if integrin expression was dysregulated in DyW muscle. 
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3.2 Integrin-〈V and beta dimer partners are upregulated in DyW muscle tissue 
 
We first sought to determine the expression pattern of integrins in adult, seven- 
week DyW mice. We found integrin-〈V gene expression was ~1.7 fold increased in DyW 
mice compared to WT mice of the same age as measured by qRT-PCR (Fig. 3.2.1).     
This was also substantiated on the protein level using CD51 ELISA (Fig. 3.2.1). Integrin- 
〈V protein levels were ~5 fold greater than age-matched WT. We also found that the beta 
dimer partners known to associate with integrin-〈V to bind and release TGF-® from the 
LLC, Integrin-®1, -®3, -®5, -®6, -®8, were all significantly upregulated in seven-week 
old DyW mice (Fig. 3.2.2). We also verified upregulation of the matricellular proteins that 
were found to be dysregulated early in DyW development and found that osteopontin, 
periostin, and fibronectin were all still significantly upregulated greater than 10-fold in 
DyW mice compared to WT mice (Fig. 3.2.3). 
3.3 Integrin-〈V localizes to the interstitium and sarcolemma in DyW mice 
 
After determining that integrin-〈V is upregulated in DyW muscle tissue we next 
examined its localization. Immunostaining with anti-CD51 (integrin-〈V) antibodies 
showed substantial expression of integrin-〈V in the muscular interstitial space (Fig. 
3.3.1). This was not surprising because there are many infiltrating cells in DyW muscle 
that are classically known to express integrin-〈V like immune cells and fibroblasts (67, 
100-102). This was further substantiated with dual staining of anti-CD11b and anti-CD51 
antibodies showing that much of the intersitital staining of integrin-〈V is located on 
macrophages (Fig. 3.3.2). What was notable, however, was the overlapping staining of 
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integrin-〈V at the sarcolemma with desmin, a prominent intermediate filament can be 
utilized as a muscle-specific co-stain. This suggested that Integrin-〈V may also localize to 
the muscle cell membrane (Fig. 3.3.1). Because integrin-〈V is not normally found on the 
membrane of adult muscle (103), we confirmed the expression on mature myofibers by 
isolating single myofibers from DyW and WT muscle and staining for CD51 (Fig. 
3.3.3). This again showed that integrin-〈V localizes to the membrane of DyW muscle, 
but not WT muscle, therefore demonstrating a shift in muscle phenotype due to 
dystrophic pathology. 
3.4 Discussion 
 
TGF-® can be freed or activated from the latent complex by multiple different 
mechanisms including pH and temperature fluctuations as well as interactions with 
reactive oxygen species, proteases, thrombospondin, and integrins (59, 104-107). 
Integrins, and specifically integrin-〈V pairs, have been shown in many cases to be 
prominent TGF-® activators via their ability to bind RGD sequences, located in the LAP 
of TGF-®1 and TGF-®3, to release TGF-® from the latent complex. This interaction is 
so critical that mice with a mutation in the RGD sequence of the LAP as well as 
inhibition of two critical –〈V heterodimers recapitulates the phenotype of TGF-®1 and –
®3 knockout mice. Integrin-〈V can activate TGF-® when in complex with all of its beta 
dimer partners Integrin-®1, -®3, -®5, -®6, and -®8-though the mechanisms of 
activation differ depending on the context of the dimer pair (63-66). We found evidence 
of significant upregulation of Integrin-〈V as well as all the aforementioned beta dimer 
pairs in adult as well as developing DyW mice. 
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Integrin-〈V®1 is a major integrin heterodimer found on the surface of tissue 
fibroblasts and myofibroblasts (67, 73) and blockade with an –〈V®1 specific antibody 
significantly reduced established fibrosis in the liver and lung (108). Integrin-〈V®3 and – 
〈V®5 are upregulated in cardiac and skin fibroblasts during fibrosis and have been shown 
to activate latent TGF-® in vitro through contraction-mediated release (102, 107)          
but therapeutically targeting these two heterodimers has shown conflicting therapeutic 
results. While genetic ablation failed to demonstrate any improvement in bleomyocin- 
induced lung fibrosis and the small molecule inhibitor of integrin-〈V®3 and –〈V®5 
actually augmented bile duct ligation and TAA-induced liver fibrosis (109, 110), genetic 
ablation of integrin-®3 protected against skin stiffness in a fibrillin-1 knockout mouse 
(111). 
The two most prominent TGF-® activating –〈V heterodimers are integrin-〈V®6 
and –〈V®8. Integrin-〈V®6 expression in most organs is quite low during homeostasis  
but its expression is significantly elevated during fibrosis (101). This heterodimer is 
mostly restricted to epithelial cells (which could explain why there is only a slight but 
significant increase in the gene expression of Integrin-®6) and activates TGF-® through 
contraction-induced conformational change of the LAP thereby releasing TGF-® from the 
LLC (68, 70). While integrin-〈V®8 binds the same sequence on the LAP it does not 
release TGF-® via contraction but instead recruits MMPs to proteolytically cleave the 
mature TGF-® cytokine from the LLC (112). Inhibition of both heterodimers through 
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genetic ablation (70, 113), antibody inhibition (114), or small molecule inhibitors (115) 
has proved to be protective against both lung and liver fibrosis. While the current study 
did not deduce what specific –〈V heterodimers are most prominent in DyW mice, future 
studies could be designed to determine which are most prominent in order to focus 
therapy potentially toward specific pairs or other proteins mechanistically regulated along 
with the prominent dimer pairs. 
The most potent pathway to inhibit integrin-mediated activation of TGF-
® however, has shown to be through inhibition of Integrin-〈V (72). Henderson et. al 
(2013) showed that genetic ablation of integrin-〈V in myofibroblasts protects mice from 
liver, lung, and kidney fibrosis (72). They further showed that administration of the small 
molecule integrin-〈V inhibitor CWHM-12 resulted in similar protective benefits against 
fibrosis as direct genetic ablation (72). Additionally, it has been shown that administration 
of CWHM-12 to mice following muscle injury with cardiotoxin resulted                          
in enhanced regeneration with minimal scar tissue (personal communication with Dr. 
Henderson). These results support further investigation into the role of integrin-〈V in 
muscle disease as well as its utility as an effective therapeutic target in reducing the 
activation of TGF-®. 
Lastly, the finding that Integrin-〈V is expressed not only in the intersitium but also 
on the sarcolemma on DyW myofibers is the first time such a change in membrane- 
associated proteins has been documented. Coupled with results presented earlier that there 
is significant dysregulation of matrix and matrix remodeling proteins as well as 
membrane receptors that interact with them, both on the infiltrating cells and muscle cells 
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themselves, opens up new avenues for investigation into the underlying mechanisms of 
how adhesion molecules such as integrins could be driving fibrosis as well as alter the 
myogenic phenotype in a dystrophic environment. 
3.5 Materials and methods 
 
3.5.1 Animal breeding and care 
 
All animals were housed at the Laboratory Animal Care Facility – Charles River Campus 
(LACF-CRC) of Boston University on a 12:12-hr light-dark cycle. Food and water were 
provided ad libitum. All procedures were performed in accordance to the protocol 
approved by the IACUC of Boston University (protocol number 13-055). Heterozygous 
B6.129 Lama2dy-W/+ mice, carrying a targeted mutation in the Lama2 gene, were kindly 
provided by Dr. Eva Engvall (Burnham Institute, La Jolla, CA, USA). Genotyping was 
done by PCR assays on tail snips using the REDExtract-N-AmpTM kit (Sigma Aldrich, St. 
Louis, MO) and mice homozygous for the mutation were used as the study animals 
(annotated DyW throughout). 
3.5.2 Muscle tissue collection 
 
Animals were then euthanized with isofluorane (Webster Veterinary, Devens, MA, USA) 
before isolating the tibialis anterior (TA), gastrocnemius/soleus complex (GS), and 
quadriceps muscles (QD). Tissues were weighed and snap frozen in liquid nitrogen for 
RNA and protein extraction. TA/GS muscles used for histology were embedded in 
Tissue-Tek OCT Compound (Sakura Finetek USA, Inc., Torrance, CA, USA) and frozen 
in isopentane (Sigma-Aldrich, St. Louis, MO, USA) chilled in liquid nitrogen. Serial 
transverse sections (7µm) were prepared using the Leica CM 1850 cryostat (Leica 
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Microsystems, Inc.) and stored at -80 ̊C (98). 
 
3.5.3 Immunohistochemistry 
 
Frozen tissue sections were incubated in Acetone for 20 minutes then left to air dry for 15 
minutes. Protocol for Mouse on Mouse (M.O.M.) serial immunostaining for frozen 
sections provided by Vector Labs (Burlingame, CA) was followed using anti-CD51 
(eBioscience, San Diego, CA), anti-desmin (Sigma Aldrich, St. Louis, MO) and anti- 
CD11b (eBioscience, San Diego, CA) antibodies 1:200 in blocking buffer for 1 hour and 
washed 2x2 in PBS. Sections were then stained with either alexafluor goat anti mouse or 
goat anti rabbit secondary antibodies for 1 hour protected from light and washed 3x5 in 
PBS. Finally, Sections were mounted with Vectashield with DAPI (Vector Labs, 
Burlingame, CA) or 2:1 Glycerol:PBS and imaged with a Nikon DSFi1 camera head 
attached to a Nikon ECLIPSE 50i light microscope system. These images were analyzed 
using NIS-Elements Basic Research 3.0 software. Single myofibers were fixed in 4% 
PFA and stained using the same protocol as frozen muscle sections with anti-CD51 and 
anti-myogenin antibodies (eBioscience, San Diego, CA). 
3.5.4 Gene expression 
 
RNA from ~25 mg liquid nitrogen snap frozen pooled hind limb muscles was extracted 
with TRIzol reagent (Invitrogen, Carlsbad, CA) according to the manufacturer’s 
instructions. 1µg RNA was reverse-transcribed with the High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems, Foster City, CA, USA). Analysis of gene 
expression was performed with TaqMan assays (Applied Biosystems, Foster City, CA, 
USA) on ABI 7300 Real Time PCR system. 18s ribosomal subunit RNA served as the 
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endogenous control and gene expression was calculated by using the ⊗⊗Ct method. 
 
3.5.5 Protein expression: ELISA 
 
Amount of integrin-〈V (CD51) was	determined using ELISA kits (Biolegend; San Diego, 
CA) following manufacturer’s instructions. Using lysis buffer containing protease and 
phosphatase inhibitor cocktails, protein was isolated from hind limb and serum samples 
of WT and DyW mice. The lysates were incubated with the capture antibody for 3 hours 
at room temperature followed by 5 washes with the wash buffer. The wells were washed 
5 times for 3 minutes each and then incubated with detection antibodies for 2 hours at 
room temperature. The wells were then washed as described above and then incubated 
with Avidin-HRP conjugates. The washing step was repeated again as above and 
incubated with the substrate for 15 minutes. The reactions were stopped subsequently and 
the absorbance was recorded at 450 and 570 nm. 
3.5.6 Single myofiber isolation 
 
Animals were euthanized by overdose of isoflurane. Fur was wetted with 70% ethanol 
and alcohol was allowed to evaporate. Extensor Digitorum Longus (EDL) muscles from 
both hind limbs were removed quickly and incubated in 2 mL DMEM containing 0.2 % 
Collagenase type I (Worthington Biomedical, Lakewood NJ, USA). Digestion time of 30 
minutes for WT and 45 minutes for DyW muscle was found optimum to release single 
myofibers from these animals respectively. Muscle was triturated gently with a wide bore 
glass pipette to release single myofibers. Single fibers were washed twice with pre- 
warmed DMEM and transferred to matrigel coated culture dish containing growth 
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medium (DMEM with 20% FCS, 1% chick embryo extract and 1x penicillin 
streptomycin). They were fed with fresh pre-warmed growth medium every 24 hours. 
3.5.7 Statistics 
 
One- and two-way ANOVA as well as student t- tests were performed using GraphPad 
Prism 6 software. Data are presented as mean ± standard deviation.		
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Fig. 3.2.1-Integrin-〈V is upregulated and overexpressed in adult DyW mice. A) 
Gene expression measured by qRT-PCR shows significant upregulation (p<0.001, n=5, t- 
test) of integrin-〈V in adult DyW mice. B) Upregulation was confirmed via ELISA 
which showed integrin-〈V is also significantly overexpressed (p<0.0001, n=5, t-test) in 
adult DyW mice. 
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Fig. 3.2.2-Integrin-〈V beta dimer partners are upregulated in adult DyW mice. A-E) 
Gene expression measured by qRT-PCR show ®-integrins known to pair with integrin- 
〈V to activate TGF-® from its latent complex are all upregulated in adult DyW mice 
(p<0.05, n=5, t-test). *=p<0.05, **=p<0.01, ***=p<0.001, ****=p<0.0001. 
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Fig. 3.2.3-Matricellular proteins are upregulated in adult DyW mice. A-C) Gene 
expression measured by qRT-PCR matricellular proteins fibronectin (FN), osteopontin 
(OPN), and periostin (PN) are all significantly upregulated (p<0.001, n=5, t-test) in adult 
DyW mice compared to age-matched WT control. ***=p<0.001, ****=p<0.0001. 
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Fig. 3.3.1-Integrin-〈V localizes to the interstitium as well as DyW sarcolemma. 
Immunostaining with anti-CD51 (Integrin-〈V) antibody (red) shows overexpression of 
integrin-〈V in the institium of DyW muscles. Overlap with desmin (green) also suggests 
that integrin-〈V also localizes to the sarcolemma of DyW myofibers. 
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Fig. 3.3.2-Integrin-〈V is expressed on macrophages. Co-staining with Mac-1 (anti- 
CD11b) shows that much of the interstitial expression of integrin-〈V localizes to 
macrophages in DyW muscle. 
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Fig. 3.3.3-Integrin-〈V is expressed on adult DyW myofibers. Immunostaining of 
single myofibers from adult DyW and WT mice confirm integrin-〈V is expressed on the 
sarcolemma of DyW but not WT myofibers. 
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Chapter 4: Evidence of myofibroblast transdifferentiation in adult DyW mice 
 
4.1 Introduction 
 
As previously mentioned, TGF-®-Integrin-〈V signaling is also intricately 
involved in the transdifferentiation of various cell types to a myofibroblastic phenotype. 
Myofibroblasts can transdifferentiate from a multitude of different cell types and are part 
of the normal wound healing process because of their ability to hyperactively secrete 
matrix material and pull on the matrix to close wounds, due to their contractile properties 
imparted by 〈-SMA stress fibers. Normally, when the originally noxious stimuli subside 
and the matrix returns to a chemically and structurally homeostatic state, the 
myofibroblasts present will undergo mass apoptosis or dedifferentiate back to their 
precursor cells. However, in response to chronic inflammation, dysregulated TGF- 
® signaling, and increased expression of matricellular proteins and Integrin-〈V, 
myofibroblast activity becomes unchecked and their ability to be hyperproliferative, 
ECM secreting, contractile cells can quickly exacerbate fibrotic pathology. Based on the 
significant upregulation of matricellular proteins, Integrin-〈V, and TGF-® signaling, all 
of which feed into myofibroblast transdifferentiation (MT), we decided to examine if 
there was any evidence of MT in DyW muscle. 
4.2 DyW fibroblasts are hyperproliferative 
 
One of the characteristics of myofibroblasts, as previously explained, is their 
hyperproliferative capacity compared to normal tissue-resident fibroblasts (76, 82, 116). 
For this reason, we examined the proliferative properties of fibroblasts isolated from 
DyW muscle in comparison to fibroblasts isolated from WT muscle at the same time 
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point. We found that not only are there significantly more fibroblasts per milligram of 
muscle tissue in DyW muscle, but when plated at equal densities, DyW fibroblasts are 
significantly more proliferative than WT fibroblasts thus suggesting they may be 
myofibroblasts (4.2.1). Of note, this hyperproliferative nature subsides after a few 
passages in culture suggesting that the environment of DyW muscle is controlling the 
myofibroblastic phenotype of these cells (data not shown). 
4.3 Myofibroblast marker proteins are upregulated and overexpressed in DyW muscle 
 
Myofibroblasts are classically denoted by the induction of alpha-smooth muscle 
actin (〈-SMA) stress fibers that imparts their ability to contract the surrounding matrix. 
Other proteins that are involved in the transdifferentiation and identification of 
myofibroblasts include the intermediate filament vimentin, platelet derived growth factor 
receptor beta (PDGFRb), and osteoblast cadherin (OB-cadherin), which allows them to 
adhere to the stiff matrices they produce. We found that mRNA transcripts for all these 
proteins were significantly upregulated in seven-week DyW mice (Fig. 4.3.1). 
Immunostaining for these markers substantiates the gene expression assays. Anti-〈-SMA 
antibodies show numerous mononuclear 〈-SMA positive cells in DyW muscle whereas in 
WT, 〈-SMA is restricted to smooth muscle cells (SMCs) in the blood vessels (Fig. 
4.3.2). Dual staining with desmin shows that many of these 〈-SMA positive cells also 
express desmin, a characteristic of mature myofibroblasts (Fig. 4.3.3). Vimentin 
immunostaining also shows an abundance of mononuclear vimentin positive cells in the 
intersitium of DyW muscle that is not seen in WT muscle. Like 〈-SMA, vimentin is 
restricted to the SMCs in the walls of the blood vessels (Fig. 4.3.4). 
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4.4 Myofibrogenesis transcription factors are upregulated and overexpressed in DyW 
muscle 
We next assayed for transcriptions factors downstream of TGF-® that are 
responsible for MT in other disease scenarios namely snail, slug, and twist as well as ®- 
catenin, and TCF4. We found that at seven weeks of age, DyW mice have significantly 
elevated mRNA transcript levels of all these proteins compared to age-matched WT mice 
(Fig. 4.4.1). Immunohistochemistry of many of these transcription factors shows the 
same trend. Anti-snail, slug, and ®-catenin staining shows an abundance of positive 
nuclei that are completely absent in WT mice (Fig. 4.4.2A–C). Taken together, the 
hyperproliferaton of DyW fibroblasts coupled with significant upregulation of the 
myofibroblast marker proteins and transcription factors provides considerable evidence 
for the presence of myofibroblast transdifferentiation in DyW mice that could be driven 
by Integrin-〈V signaling and playing a critical role in driving disease progression. 
4.5 Discussion 
 
In addition to its role in activating TGF-® from the latent complex, Integrin-〈V is 
also directly involved in the transdifferentiation of various cell types to myofibroblasts 
(73, 99). During times of wound healing, fibroblasts and other infiltrating or resident cells 
can become activated to become myofibroblasts-a specialized ECM secreting, highly 
proliferative and contractile cell that is critical to normal wound repair but can become 
pathological in fibrotic scenarios (74, 76, 77). The role of Integrin-〈V in this process is 
well documented (73, 78, 117). 
One way in which cell types are influenced to become myofibroblasts is through 
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their sensation of the surrounding ECM milieu (75, 81, 85). Changes in the surrounding 
matrix (as would occur during active fibrosis) instruct the cell to change the way it 
interacts with that matrix, mainly through changing cell-surface integrin repertoire (77, 
84, 85, 101). Specific ECM remodeling that can induce these changes include increased 
expression of fibronectin and other matricellular proteins like osteopontin and periostin, 
all of which we found to be overexpressed in DyW muscle tissue. These changes in the 
ECM and integrin ligands activate integrins from their low affinity “off” states to their 
high affinity “on” states. Integrin activation further induces signaling from either an 
outside in, i.e. traditional ligand-mediated signaling, or inside out, where adaptor proteins 
intracellularly induce the way the integrin behaves in the ECM. In terms of integrin-〈V, 
activation stimulates it to bind and release TGF-® from the latent complex which initiates 
TGF-® signaling as well as Akt signaling which is also known to be hyperactive in DyW 
muscle tissue (50). The crosstalk of these pathways induces the expression of MT related 
transcription factors like snail, slug, and twist in addition to ®-catenin. These 
transcription factors further facilitate the expression of other proteins involved in              
myofibroblast formation like 〈-SMA, vimentin, PDGFRb, and ob-cadherin in addition to 
further increases in modified ECM proteins suited for the myofibroblast 
microenvironment. It also facilitates increased expression of integrin-〈V and beta partners 
at the cell surface. Together, these pathways create a circle of reciprocal regulation that 
can act as a double-edged sword toward exacerbating fibrotic pathology (62-66, 72, 73, 
99). 
We found significant evidence of transdifferentiation occurring in adult DyW 
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mice. Not only was there significant gene upregulation of myofibroblast related proteins 
like 〈-SMA, vimentin, PDGFRβ, and ob-cadherin as well as transcription factors snail, 
slug, twist, there was also evidence of significant protein overexpression of the proteins  
in the muscle tissue. Additionally, we found that fibroblasts inherent to DyW muscle are 
hyperproliferative in comparison to WT fibroblasts, a key characteristic that distinguishes 
resident tissue fibroblasts from myofibroblasts. This suggests that myofibroblast 
transdifferentiation is likely occurring in DyW muscle and could be playing a major role 
in driving fibrotic pathology. 
4.6 Materials and methods 
 
4.6.1 Animal breeding and care 
 
All animals were housed at the Laboratory Animal Care Facility – Charles River Campus 
(LACF-CRC) of Boston University on a 12:12-hr light-dark cycle. Food and water were 
provided ad libitum. All procedures were performed in accordance to the protocol 
approved by the IACUC of Boston University (protocol number 13-055). Heterozygous 
B6.129 Lama2dy-W/+ mice, carrying a targeted mutation in the Lama2 gene, were kindly 
provided by Dr. Eva Engvall (Burnham Institute, La Jolla, CA, USA). Genotyping was 
done by PCR assays on tail snips using the REDExtract-N-AmpTM kit (Simga Aldrich, St. 
Louis, MO) and mice homozygous for the mutation were used as the study animals 
(annotated DyW throughout). 
4.6.2 Muscle tissue collection 
 
Animals were then euthanized with isofluorane (Webster Veterinary, Devens, MA, USA) 
before isolating the tibialis anterior (TA), gastrocnemius/soleus complex (GS), and 
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quadriceps muscles (QD). Tissues were weighed and snap frozen in liquid nitrogen for 
RNA and protein extraction. TA/GS muscles used for histology were embedded in 
Tissue-Tek OCT Compound (Sakura Finetek USA, Inc., Torrance, CA, USA) and frozen 
in isopentane (Sigma-Aldrich, St. Louis, MO, USA) chilled in liquid nitrogen. Serial 
transverse sections (7µm) were prepared using the Leica CM 1850 cryostat (Leica 
Microsystems, Inc.) and stored at -80 ºC (98). 
4.6.3 Immunohistochemistry 
 
Frozen tissue sections were incubated in Acetone for 20 minutes then left to air dry for 15 
minutes. Protocol for Mouse on Mouse (M.O.M.) serial immunostaining for frozen 
sections provided by Vector Labs (Burlingame, CA) was followed using anti-snail, anti- 
slug, anti-b-catenin (Cell Signaling Technology, Danvers, MA) antibodies 1:200 in 
blocking buffer for 1 hour and washed 2x2 in PBS. Sections were then stained with either 
alexafluor goat anti mouse or goat anti rabbit secondary antibodies for 1 hour protected 
from light and washed 3x5 in PBS. Finally, Sections were mounted with Vectashield with 
DAPI (Vector Labs, Burlingame, CA) or 2:1 Glycerol:PBS and imaged with a Nikon 
DSFi1 camera head attached to a Nikon ECLIPSE 50i light microscope system. These 
images were analyzed using NIS-Elements Basic Research 3.0 software. 
4.6.4 Gene expression 
 
RNA from ~25 mg liquid nitrogen snap frozen pooled hind limb muscles was extracted 
with TRIzol reagent (Invitrogen, Carlsbad, CA) according to the manufacturer’s 
instructions. 1µg RNA was reverse-transcribed with the High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems, Foster City, CA, USA). Analysis of gene 
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expression was performed with TaqMan assays (Applied Biosystems, Foster City, CA, 
USA) on ABI 7300 Real Time PCR system. 18s ribosomal subunit RNA served as the 
endogenous control and gene expression was calculated by using the ⊗⊗Ct method. 
4.6.5 Fibroblast isolation and cell culture 
 
Fibroblasts were isolated from pooled hindlimb muscles of 7-week DyW and WT mice. 
Extracted muscles were minced in sterile HBSS in a petri dish to increase surface area 
exposed to pronase. Connective tissue was digested from homogenates by exposing to 
pronase (Sigma-Aldrich; CAT #10165921001) for 45 minutes at 37 ºC. The homogenate 
agitated vigorously by pipetting every 15 minutes to disrupt basement membrane and 
ECM. Following pronase incubation, muscle homogenates were filtered through 70∝m 
and 40∝m sterile filters and spun for 10 minutes at 1000 RPM. Following spin, pellet was 
resuspended in DMEM media supplemented with 10% FBS and 1% Pen-Strep and plated 
for 30 minutes on a non-coated tissue culture plate to allow fibroblasts to adhere. Media 
was removed (along with unadhered cells) and changed with fresh medium. Fibroblasts 
were cultured to 80% confluence before splitting and subsequent seeding for 
experimentation. 
4.6.6 Statistics 
 
One- and two-way ANOVA as well as student t- tests were performed using GraphPad 
Prism 6 software. Data are presented as mean ± standard deviation. 
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Fig. 4.2.1-DyW fibroblasts are hyperproliferative in culture. A) Isolation of 
fibroblasts from DyW and WT muscle tissue show there are more fibroblasts per mg of 
muscle tissue in DyW muscle. B) When plated at equal density, DyW fibroblasts are also 
hyperproliferative compared to WT fibroblasts. 
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Fig. 4.3.1- Myofibroblast markers are upregulated in adult DyW mice. A-D) Gene 
expression measured by qRT-PCR shows significant upregulation (p<0.01, n=4, t-test) of 
proteins known to be upregulated in myofibroblasts including stress fibers containing 〈- 
smooth muscle actin (A), the intermediate filament vimentin, (B), platelet derived growth 
factor receptor beta (C), and osteoblast cadherin (D). **=p<0.01, ****=p<0.0001. 
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Fig. 4.3.2-DyW muscle contains mononuclear 〈-SMA positive cells. Staining with 
anti-〈-SMA antibody shows multiple mononuclear 〈-SMA positive cells (arrows) in 
DyW muscle tissue that are not apparent in WT muscle. 〈-SMA staining appears 
localized to blood vessels in WT mice. 
 
 
 
  
 
Fig. 4.3.3-Many 〈-SMA positive cells co-express desmin. Co-staining with anti-〈- SMA 
and anti-desmin antibodies shows that many of the 〈-SMA positive cells are also 
expressing the intermediate filament desmin, further supporting they are myofibroblasts. 
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Fig. 4.3.4-DyW muscle harbors mononuclear vimentin positive cells. 
Immmunostaining with anti-vimentin antibody shows numerous vimentin postive 
mononuclear cells not associated with blood vessels. WT tissue only shows vimentin 
expression around blood vessels. NB: B.V=blood vessel. 
B.V.	
B.V.	
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Fig. 4.4.1-Myofibroblast-related transcription factors are upregulated in DyW 
muscle. A-E) Gene expression measured by qRT-PCR shows significant upregulation 
(p<0.01, n=4, t-test) of transcription factors known to govern myofibroblast 
transdifferentiation including the bHLH transcription factors snail (A), slug (B), and 
twist1 (C), as well as TCF4 (D) and ®-catenin (E). **=p<0.01, ***=p<0.001, 
****=p<0.0001. 
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Fig. 4.4.2A-DyW mice harbor numerous snail positive cells. Immunostaining with 
anti-snail antibody shows a substantial number of snail positive cells in DyW muscle that 
are completely absent in WT muscle. 
 
 
 
 
 
  
 
Fig. 4.4.2B-DyW mice harbor numerous slug positive cells. Immunostaining with anti- 
slug antibody shows a substantial number of slug positive cells in DyW muscle that are 
completely absent in WT muscle. 
DyW	 WT	
DyW	 WT	
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Fig. 4.4.2C-DyW mice harbor numerous ®-catenin positive cells. Immunostaining 
with anti-®-catenin antibody shows a substantial number of ®-catenin positive cells 
in DyW muscle that are completely absent in WT muscle. 
DyW	 WT	
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Chapter 5: Integrin dysregulation and myofibroblast transdifferentiation could be 
playing an etiological role in the MDC1A phenotype 
5.1 Introduction 
 
Because MDC1A is a congenital disease and presents at/near birth, the most 
relevant data concerning disease progression comes from early time points. As stated 
earlier, when attempting to discern relevant targets and timelines for therapeutic 
intervention it is imperative to identify the key underlying molecular signatures from the 
onset of disease and early progression. Following elucidation of integrin dysregulation 
and the presence of myofibroblast transdifferentiation in adult DyW mice, we next asked 
the question if the dysregulation of these pathways could potentially be etiological to 
DyW and thus potentially MDC1A pathology. 
5.2 Integrin dysregulation is apparent as early as week one postnatal 
 
Gene expression, via mRNA transcripts levels, of α and β integrins as well as a 
related downstream effector protein Integrin-Linked Kinase (ILK) were measured from 
pooled hind limb muscle of DyW and WT mice collected from at postnatal weeks one, 
two, three, and four (Fig. 5.2.1). Integrin-〈V was found to be upregulated in DyW mice 
over age-matched WT mice at all time points and peaking in relative expression at week 
four. Integrin-〈5, also known as the fibronectin receptor and known to play roles in 
macrophage recruitment and NF-⎢B signaling (118), was also upregulated at weeks one, 
three, and four and peaking in relative expression at week four. 
The gene expression of the relevant beta dimer partners of Integrin-〈V was also 
examined (Fig. 5.2.1). Integrin-®1 and –®3 were upregulated in DyW mice compared to 
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age-matched WT mice at weeks two, three, and four, peaking in relative expression at 
week four. Integrin-®5 was upregulated over age-matched WT mice at all time points 
though its highest relative expression was found to be week two postnatal following 
which its expression decreased though was still significantly greater than WT mice. 
Integrin-®6 was found only to be upregulated, slightly, at week three while Integrin-®8 
was upregulated at weeks three and four. ILK was upregulated in DyW at weeks two, 
three, and four, peaking in expression again at week four (Fig. 5.2.1). 
5.3 Growth factor and downstream genes are dysregulated from week one postnatal 
 
We next examined gene expression of relevant growth factors that feed into and 
drive fibrotic pathology (Fig. 5.3.1). Looking at the three TGF-® isoforms (TGF-®1, 
®2, ®3), TGF-®2 was only upregulated, slightly, at week four. TGF-®1 was 
upregulated at all time points, peaking in relative expression at week four while TGF-®3 
was upregulated at weeks two, three, and four, peaking in expression at week two. It is 
interesting to note that of the three isoforms only TGF-®1 and –®3 are upregulated. 
Since only TGF-®1 and 
–®3 have RGD domains on the LAP and TGF-®2 does not, they would seem most 
relevant to fibrosis induced by Integrin-〈V. 
We next examined gene expression levels of connective tissue growth factor 
(CTGF; also known as CCN2) and bone morphogenic protein 1 (BMP1) (Fig. 5.3.1). 
CTGF is another matricellular protein known to be transcriptionally activated by TGF-
® signaling and acts as a modulator of ECM-ECM (including interactions between 
growth factors) and cell-ECM (including interacting with integrins) interactions involved 
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fibrosis 
(57). Interestingly, while TGF-® isoforms are upregulated very early on and persist 
 
throughout development, CTGF was only significantly upregulated, transcriptionally, at 
week four. BMP1 is also known to be transcriptionally activated by TGF-® signaling 
and also is known to activate TGF-® in the ECM via cleavage from the latent complex 
(119). We found that BMP1 expression, unlike CTGF, was upregulated over age-
matched WT mice at weeks two, three, and four, increasing in relative expression every 
week and peaking in expression at week four (Fig. 5.3.1). 
We next looked at other relevant ECM proteins that are involved in integrin 
signaling, fibrosis, and myofibroblast transdifferentiation that were not examined in the 
first study. In addition to the previously mentioned extra/matricellular proteins (Col1a, 
osteopontin, periostin, fibronectin, MMP2, MMP9, and TIMP1), we also examined gene 
expression of Collagen VI, a known constituent of dense fibrotic tissue and the 
myofibroblast matrix (77), and versican, a pericellular glycosaminoglycan that has been 
shown to modulate the fibroblast to myofibroblast transition and enhance TGF-
® signaling (Fig. 5.3.2) (120). We found that both of these matrix proteins were 
upregulated over age-matched WT mice at weeks two, three, and four, increasing in 
relative expression in each week and peaking in relative expression at week four. 
5.4 Myofibroblast transdifferentiation markers and transcription factors are 
dysregulated as early as week one postnatal 
Lastly, we looked at the myofibroblast protein markers (Fig. 5.4.1) and the 
transcription factors (Fig. 5.4.2) that govern myofibroblast transdifferentiation in 
developing DyW mice.. We found that 〈-SMA, a major marker of myofibroblasts and 
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important to impart contractility to myofibroblasts, gene expression was not significantly 
upregulated over age-matched WT mice at any time points from postnatal weeks one 
through four. The intermediate filament vimentin, however, was upregulated at all time 
points, increasing in relative expression each week and peaking in relative expression at 
week four. Platelet Derived Growth Factor receptor beta (PDGFRβ), a major receptor on 
the cell surface of myofibroblasts, was also found to up transcriptionally upregulated in 
DyW mice compared to age-matched WT mice at postnatal weeks three and four, 
peaking in expression at week four. Likewise, OB-cadherin, a myofibroblast cell surface 
protein critical to adhering to stiff matrices such as seen in fibrotic plaques, was 
upregulated at weeks two and three and exhibiting a very large increase in expression at 
postnatal week four. 
Transcription factors known to govern myofibroblast transdifferentiation are also 
upregulated in developing DyW mice (Fig. 5.4.2). The three main transcription factors 
most involved in epithelial to mesenchymal transition (EMT), are the basic helix loop 
helix (bHLH) transcription factors snail, slug, and twist, were found to all be upregulated 
in DyW mice compared to age-matched WT mice. Snail was found to be upregulated in 
postnatal weeks three and four, peaking in expression at week four; slug and twist was 
found to be upregulated at weeks two, three, and four, increasing in relative expression 
and peaking in relative expression at week four. We then measured the transcript levels 
of T-cell factor 4 (TCF4) as it is known to work in complex with ®-catenin to transcribe 
MT genes, and found that it was also upregulated in weeks three and four, peaking in 
relative expression on week four. 
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5.5 Discussion 
 
We show here that integrin dysregulation and genes relevant to myofibrogenesis 
are dysregulated throughout DyW development. As stated earlier, DyW mice have a very 
limited capacity for regeneration, exhibit almost no postnatal growth compared to their 
WT littermates, and show rampant fibrosis by week two postnatal. Based on these data, it 
is possible that myofibroblasts are not only present but may be critical players in driving 
the early pathology of DyW mice. 
While many different cell types have been shown to be susceptible to 
transdifferentiation, including smooth muscle cells, fibrocytes, pericytes, and tissue- 
resident fibroblasts, it is also possible that this process is not limited in these cell types 
and may also occur in myoblasts. Indeed, it has been shown that C2C12 myoblasts have 
the ability to undergo transdifferentiation when exposed to TGF-® in vitro as well as in 
vivo (86, 121). This elicits an interesting hypothesis regarding the gene expression data 
collected from developing DyW mice where we found increased integrin-〈V, 
matricellular protein, myofibroblast transdifferentiation markers, and increased TGF-
® signaling. It is plausible, then, to postulate that myoblasts activated during 
regeneration are being influenced by the fibrotic microenvironment to transdifferentiate 
to myofibroblasts. 
Perhaps the most interesting support of this hypothesis is that all of the genes 
related to myofibrogenesis seem to experience a spike after two weeks. While many 
genes were upregulated during postnatal weeks one and two, many of the genes remained 
consistent with WT expression levels up to two weeks of age. After this point, however, 
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most, if not all, became significantly elevated. When comparing these expression patterns 
to the gross postnatal growth experienced by mice at this time point, week three begins 
the major growth spurt that WT mice experience. DyW mice, on the other hand, exhibit a 
flat growth curve and experience almost no postnatal growth whatsoever (51). One 
possibility is that satellite cells, migrating from their niche inside the basal lamina out into 
the ECM to fuse with regenerating muscle fibers, become coerced by the extracellular 
environment to transdifferentiate to myofibroblasts. Previous research showing            
that the injection of recombinant TGF-® into injured skeletal muscle induces the 
transdifferentiation of myoblasts to myofibroblasts (87) supports this hypothesis. A 
similar phenomenon was also seen in mdx mice. Pessina et. al (2015) showed that in 
response to chronic TGF-® signaling dysregulation in dystrophin-deficient mdx mice, 
cells of muscular origins lose their muscular identity and gain a plasticity toward a 
mesenchymal-fibrogenic cell fate thereby precluding them from normal muscle 
regeneration (122). Taken together, it is possible that the gross deficiencies in satellite 
cell-driven postnatal growth could be due to a loss of muscle cell phenotype towards a 
myofibroblast-like phenotype thereby further compromising muscle growth and driving 
fibrotic pathology. 
In addition to the role these transdifferentiation proteins play in driving fibrosis, 
the myofibroblast-related transcription factors also play a direct role in obstructing 
myogenesis (123, 124). It has been shown that snail, slug, and twist all have deleterious 
effects on myogenesis, specifically on differentiation. These bHLH transcriptions factors 
are part of the intricate enhancer switching process from proliferation to differentiation 
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during myogenesis. An increased presence of these proteins does not allow enhancer 
switching during differentiation and block myoD from transcribing myogenic 
differentiation genes thus inhibiting proper myogenesis (123, 125). 
Taken together, the developmental expression data suggest there is very early 
dysregulation of integrin expression and an abundance of myofibroblast markers. While 
future studies are needed to delineate the cells undergoing myofibroblast 
transdifferentiation as well as its (potential) relation to the primary genetic defect, these 
results suggest that integrin signaling and myofibroblast transdifferentiation may be 
playing key etiological roles in driving fibrosis and preventing postnatal growth in DyW 
mice and therefore are attractive targets for therapy implementation. 
5.6 Materials and methods 
 
5.6.1 Animal breeding and care 
 
All animals were housed at the Laboratory Animal Care Facility – Charles River Campus 
(LACF-CRC) of Boston University on a 12:12-hr light-dark cycle. Food and water were 
provided ad libitum. All procedures were performed in accordance to the protocol 
approved by the IACUC of Boston University (protocol number 13-055). Heterozygous 
B6.129 Lama2dy-W/+ mice, carrying a targeted mutation in the Lama2 gene, were kindly 
provided by Dr. Eva Engvall (Burnham Institute, La Jolla, CA, USA). Genotyping was 
done by PCR assays on tail snips using the REDExtract-N-AmpTM kit (Simga Aldrich, St. 
Louis, MO) and mice homozygous for the mutation were used as the study animals 
(annotated DyW throughout). 
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5.6.2 Muscle tissue collection 
 
Animals were then euthanized with isofluorane (Webster Veterinary, Devens, MA, USA) 
before isolating the tibialis anterior (TA), gastrocnemius/soleus complex (GS), and 
quadriceps muscles (QD). Tissues were weighed and snap frozen in liquid nitrogen for 
RNA and protein extraction. TA/GS muscles used for histology were embedded in 
Tissue-Tek OCT Compound (Sakura Finetek USA, Inc., Torrance, CA, USA) and frozen 
in isopentane (Sigma-Aldrich, St. Louis, MO, USA) chilled in liquid nitrogen. 
5.6.3 Gene expression 
 
RNA from ~25 mg liquid nitrogen snap frozen pooled hind limb muscles was extracted 
with TRIzol reagent (Invitrogen, Carlsbad, CA) according to the manufacturer’s 
instructions. 1µg RNA was reverse-transcribed with the High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems, Foster City, CA, USA). Analysis of gene 
expression was performed with TaqMan assays (Applied Biosystems, Foster City, CA, 
USA) on ABI 7300 Real Time PCR system. 18s ribosomal subunit RNA served as the 
endogenous control and gene expression was calculated by using the ⊗⊗Ct method. 
5.6.4 Statistics 
 
One- and two-way ANOVA as well as student t- tests were performed using GraphPad 
Prism 6 software. Data are presented as mean ± standard deviation. 
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Fig. 5.2.1-Integrin subunits are dysregulated during DyW development. Gene 
expression measured by qRT-PCR show that Integrin-〈V, as well as Integrin-〈5, and beta 
subunits known to pair with Integrin-〈V and activate TGF-®, are upregulated throughout 
DyW development. All subunits are significantly upregulated (p<0.05, n=4, two-way 
ANOVA) in weeks 3 and 4 with the exception of Integrin-®6 at week 4. Key signaling 
protein downstream of Integrin-〈V, Integrin-linked kinase, is also significantly (p<0.001, 
n=4, two-way ANOVA). upregulated in weeks 2-4 * denotes significance between age-
matched DyW and WT. # denotes significance between DyW groups. 
*=p<0.05, **=p<0.01, ***=p<0.001, ****=p<0.0001. Trend applies to # as well. 
Fo
ld
 c
ha
ng
e 
ov
er
 a
ge
-m
at
ch
ed
 W
T 
Fo
ld
 c
ha
ng
e 
ov
er
 a
ge
-m
at
ch
ed
 W
T 
Fo
ld
 c
ha
ng
e 
ov
er
 a
ge
-m
at
ch
ed
 W
T 
Fo
ld
 c
ha
ng
e 
ov
er
 a
ge
-m
at
ch
ed
 W
T 
77 	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.3.1-Fibrotic growth factors are dysregulated throughout DyW development. 
A-E) Gene expression measured by qRT-PCR shows that growth factors known to drive 
fibrosis including TGF-® isoforms 1 (A), 2 (B), and 3 (C), CTGF (D), and BMP1 (E) are 
significantly dysregulated (p<0.01, n=4, two-way ANOVA throughout DyW postnatal 
development. Interestingly, TGF-® isoforms 1 and 3 show most dysregulation and are the 
two isoforms that have RGD sequences in their LAP and therefore are the only ones that 
can be activated by Integrin-〈V. * denotes significance between age-matched DyW and 
WT. # denotes significance between DyW groups. *=p<0.05, **=p<0.01, ***=p<0.001, 
****=p<0.0001. Trend applies to # as well. 
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Fig. 5.3.2-ECM proteins that contribute to myofibroblast transdifferentiation are 
upregulated during DyW development. A-B) Gene expression measured by qRT-PCR 
show significant upregulation of Col6a (A) and the proteoglycan versican (B) in postnatal 
weeks 2-4. * denotes significance between age-matched DyW and WT. # denotes 
significance between DyW groups. *=p<0.05, **=p<0.01, ***=p<0.001, 
****=p<0.0001. Trend applies to # as well. 
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Fig. 5.4.1-Myofibroblast markers are dysregulated in developing DyW mice. A-D) 
Gene expression measured by qRT-PCR shows significantly dysregulation (p<0.05, n=4, 
two-way ANOVA) of proteins found on myofibroblasts including vimentin (B), platelet 
derived growth factor receptor beta (C), and osteoblast cadherin (D). Interestingly, alpha- 
SMA is not transcriptionally upregulated during DyW development (A). * denotes 
significance between age-matched DyW and WT. # denotes significance between DyW 
groups. *=p<0.05, **=p<0.01, ***=p<0.001, ****=p<0.0001. Trend applies to # as well. 
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Fig. 5.4.2-Myofibroblast transdifferentiation transcription factors are dysregulated 
throughout DyW development. A-D) Gene expression measured by qRT-PCR show 
significant dysregulation (p<0.01, n=4, two-way ANOVA) of transcription factors known 
to drive myofibroblast transdifferentiation including the bHLH transcription factors snail 
(A), slug (B), twist1 (C), as well as TCF4 (D) in postnatal weeks 2-4. . * denotes 
significance between age-matched DyW and WT. # denotes significance between DyW 
groups. *=p<0.05, **=p<0.01, ***=p<0.001, ****=p<0.0001. Trend applies to # as well. 
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Chapter 6: Losartan attenuates integrin and myofibrogenesis dysregulation 
 
(N.B. some of the following work appears in Accorsi, A., Mehuron, T., Kumar, A., Rhee, 
 
Y. and Girgenrath, M. (2015) Integrin dysregulation as a possible driver of matrix 
remodeling in Laminin-deficient congenital muscular dystrophy (MDC1A). Journal of 
Neuromuscular Diseases, 2, 51–61. The final publication is available at IOS Press 
through http://dx.doi.org/DOI:10.3233/JND-140042) 
6.1 Introduction 
 
As previously stated, there currently remains no effective means of therapy for children 
with MDC1A besides palliative care. There have however, been a multitude of studies 
utilizing various postnatal therapies that have shown efficacy in models of MDC1A (49, 
50, 126-128). One such therapy that has gained traction for its ability to act as a potent 
anti-inflammatory and anti-fibrotic agent is the Angiotensin II type 1 receptor (AT1) 
blocker, Losartan. Losartan is especially appealing because it is already an FDA 
approved drug and safe for the use in children (129) and thus could be a relatively quick 
route to the clinic. Losartan has been verified in multiple models of fibrosis including 
kidney, lung, and liver fibrosis, as well as in MDC1A mouse models (130-134). While it 
has been shown that Losartan is able to act as an anti-inflammatory and anti-fibrotic 
agent via downregulation of TGF-® signaling, theoretically through the inhibition of 
AT1-mediated phosphorylation of smad2/3 (135), the full mechanism has yet to be 
elucidated. For this reason, we sought to determine if Losartan also affected matricellular 
protein, integrin-〈V expression and therefore potentially TGF-® activation in an effort to 
understand some of the anti-fibrotic properties of Losartan. 
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6.2 Losartan attenuates integrin dysregulation 
 
We first examined the expression of integrin-〈V as well as integrin-〈5 in response 
to Losartan treatment starting at week two postnatal delivered ad libitum in the drinking 
water. We found that, following Losartan treatment, integrin-〈V gene (measured by qRT-
PCR) and protein (measured by ELISA) expression were significantly       reduced 
compared to untreated DyW mice to expression levels not statistically different from WT 
(Fig. 6.2.1). Integrin-〈5 showed the same trend. In response to Losartan, Integrin-〈5 gene 
and protein levels were significantly reduced to levels no different than WT levels (Fig. 
6.2.1). The gene expression of the known integrin-〈V beta dimer partners was also 
examined. All beta integrins, including Integrin-®1, -®3, -®5, -®6, and – ®8, like the 
alpha integrins, were significantly reduced to gene expression levels no different than WT 
mice (Fig. 6.2.2). 
We also examined the expression pattern of integrin-〈V protein following 
Losartan administration. Firstly, we found that integrin-〈V expression in the interstitium 
was reduced in response to Losartan. This was probed further with Mac-1 (anti-CD11b) 
staining and found that the reduction in interstitial –〈V staining was mainly due to a 
decrease in infiltrating macrophages as there were much less Mac-1/integrin-〈V co- 
positive cells in DyW muscle tissue following Losartan treatment (Fig. 6.2.3). Co- 
staining with desmin also revealed that the apparent staining of Integrin-〈V on the 
sarcolemma of DyW muscle fibers was also reduced in response to Losartan as can be 
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seen by no perceived overlap between desmin and integrin-〈V in the costain images (Fig. 
6.2.4). 
6.3 Losartan attenuates dysregulation of matricellular proteins, growth factors, 
myofibrogenesis-related proteins 
We next looked at the gene expression of growth factors, matricellular proteins, 
and myofibroblast markers/transcription factors previously mentioned to be upregulated 
in adult DyW mice. We first examined if matricellular protein gene expression was 
reduced in response to Losartan and found that osteopontin, periostin, and fibronectin 
were all significantly reduced to levels comparable to WT expression following Losartan 
administration (Fig. 6.3.1). We also found that the gene expression of the two RGD 
containing TGF-® isoforms (TGF-®1 and TGF-®3) were significantly upregulated in 
seven-week DyW mice and were reduced to WT expression levels in response to 
Losartan. The same was seen with the TGF-® activating BMP1 which was also 
significantly upregulated in untreated DyW mice and reduced back to WT levels in 
response to Losartan (Fig. 6.3.2). Myofibroblast markers showed similar trends. The 
major myofibroblast marker 〈-SMA as well as the intermediate filament vimentin and 
major cell surface receptors PDGFRb and ob-cadherin, previously shown to be 
upregulated in untreated adult DyW mice, were all significantly reduced to expression 
levels similar to WT levels (Fig. 6.3.3). The same held true for the major transcription 
factors governing myofibroblast transdifferentiation. The bHLH transcription factors 
snail, slug, twist, as well as TCF4 and ®-catenin were all significantly reduced in 
response to Losartan to expression levels comparable to WT levels (Fig. 6.3.4). Of note, 
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both twist and ®-catenin gene expression was significantly less than WT levels. 
 
6.4 Anti-fibrotic effects of Losartan can be measured in the serum 
 
Because the role of Integrin-〈V in TGF-® signaling is to activate it from the latent 
complex, we next looked at the levels of latent and active TGF-® by serum ELISA. Not 
surprisingly, we found that both latent and active TGF-® were found to be overexpressed 
in untreated DyW mice. Interestingly, latent TGF-® remained                        
overexpressed in Losartan-treated DyW mice but active TGF-® was significantly reduced 
(Fig. 6.4.1) in response to Losartan treatment therefore it is possible that the 
downregulation of TGF-® signaling due to Losartan treatment could be due to a decrease 
in TGF-® activation via downregulation of Integrin-〈V expression. Lastly, we examined 
serum levels of TIMP1, previously shown to be upregulated in developing DyW mice and 
has also been implicated in fibrosis and myofibroblast transdifferentiation dependent      
on Integrin-〈V. We found that TIMP1 is overexpressed in the sera of DyW mice and is 
also significantly reduced back to WT levels in response to Losartan (Fig. 6.4.2). Because 
serum extraction is a relatively non-invasive procedure, it is possible that examining the 
expression of TIMP1 and latent vs. active TGF-® is not only useful in this context, but 
can also be applied to be used as a biomarker for fibrosis as well as therapy-induced 
amelioration. 
6.5 Discussion 
 
We found that in response to Losartan, integrin-〈V gene and protein expression, 
including in the matrix and on myofibers, was rescued. Additionally, we found that a 
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matricellular protein expression and beta dimer partner upregulation was also 
significantly reduced to levels comparable to WT expression levels. 
The relationship between the Renin-Angiotensin system and integrin expression 
was demonstrated by Kawano et. al (2000) (136). They showed that Angiotensin II 
induced upregulation of integrin-〈V as well as its beta partners -®1, -®3, -®5 and that 
co- incubation with an angiotensin II type 1 receptor blocker, like Losartan, prevented 
upregulation of the integrins in rat cardiac fibroblasts. They also showed that AngII 
caused upregulation of matricellular proteins osteopontin and fibronectin, which was also 
blocked by treatment with Losartan (136). 
In addition to integrins and matricellular proteins, Losartan also attenuated 
expression of myofibroblast markers and transcription factors. This confirms results that 
showed Losartan blocked increases in 〈-SMA and ColI mRNA and therefore 
transdifferentiation of human lung fibroblasts treated with Ang II (137). Similar results 
were found in mitral valve cardiac endothelial cells that were treated with Losartan 
showing that 〈-SMA as well as snail and slug expression were reduced and therefore 
endothelial to myofibroblast transdifferentiation (EndMT) were inhibited following the 
administration of Losartan (138). 
We also show that serum levels of TIMP1 are significantly elevated in seven- 
week DyW mice and are reduced to levels comparable to WT following Losartan 
administration. Interestingly, integrin-〈V antagonists can induce significant 
downregulation of TIMP1 (139). Collectively, our results suggest that integrins, 
specifically integrin-〈V, could serve as a key component in the induction of TGF-®- 
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mediated fibrosis in DyW mice, and that it may be a nodal point for the Losartan- 
mediated reduction in fibrosis. 
Finally, in response to Losartan, we see that activated TGF-® is significantly 
reduced while latent TGF-® remains unchanged. This finding is of significance because 
as previously mentioned, that Integrin-〈V containing dimers facilitate the release of 
TGF-® from the large latent complex (LLC) (63-66, 68, 70, 72, 73). The finding that 
only activated TGF-® is reduced in response to Losartan while latent TGF-® remains 
unchanged further supports the notion that Integrin-〈V could be a key player in mediating 
fibrotic pathology in MDC1A via TGF-® activation. 
6.6 Materials and Methods 
 
6.6.1 Animal breeding and care 
 
All animals were housed at the Laboratory Animal Care Facility – Charles River Campus 
(LACF-CRC) of Boston University on a 12:12-hr light-dark cycle. Food and water were 
provided ad libitum. All procedures were performed in accordance to the protocol 
approved by the IACUC of Boston University (protocol number 13-055). Heterozygous 
B6.129 Lama2dy-W/+ mice, carrying a targeted mutation in the Lama2 gene, were kindly 
provided by Dr. Eva Engvall (Burnham Institute, La Jolla, CA, USA). Genotyping was 
done by PCR assays on tail snips using the REDExtract-N-AmpTM kit (Simga Aldrich, St. 
Louis, MO) and mice homozygous for the mutation were used as the study animals 
(annotated DyW throughout). Losartan treatment was started at two weeks post-natal and 
continued until collection at seven weeks of age. Losartan was provided in the drinking 
water ad libitum (600mg/L, Cozaar by Merck pharmaceuticals) and supplemented with 
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25g/L of sucrose to increase palatability. 
 
6.6.2 Muscle tissue collection 
 
Animals were then euthanized with isofluorane (Webster Veterinary, Devens, MA, USA) 
before isolating the tibialis anterior (TA), gastrocnemius/soleus complex (GS), and 
quadriceps muscles (QD). Tissues were weighed and snap frozen in liquid nitrogen for 
RNA and protein extraction. TA/GS muscles used for histology were embedded in 
Tissue-Tek OCT Compound (Sakura Finetek USA, Inc., Torrance, CA, USA) and frozen 
in isopentane (Sigma-Aldrich, St. Louis, MO, USA) chilled in liquid nitrogen. Serial 
transverse sections (7µm) were prepared using the Leica CM 1850 cryostat (Leica 
Microsystems, Inc.) and stored at -80 ̊C (98). 
6.6.3 Immunohistochemistry 
 
Frozen tissue sections were incubated in Acetone for 20 minutes then left to air dry for 15 
minutes. Protocol for Mouse on Mouse (M.O.M.) serial immunostaining for frozen 
sections provided by Vector Labs (Burlingame, CA) was followed using anti-CD51 
(eBioscience, San Diego, CA), anti-desmin (Sigma Aldrich, St. Louis, MO), anti-CD11b 
(eBioscience, San Diego, CA) antibodies 1:200 in blocking buffer for 1 hour and washed 
2x2 in PBS. Sections were then stained with either alexafluor goat anti mouse or goat anti 
rabbit secondary antibodies for 1 hour protected from light and washed 3x5 in PBS. 
Finally, Sections were mounted with Vectashield with DAPI (Vector Labs, Burlingame, 
CA) or 2:1 Glycerol:PBS and imaged with a Nikon DSFi1 camera head attached to a 
Nikon ECLIPSE 50i light microscope system. These images were analyzed using NIS- 
Elements Basic Research 3.0 software. 
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6.6.4 Gene expression 
 
RNA from ~25 mg liquid nitrogen snap frozen pooled hind limb muscles was extracted 
with TRIzol reagent (Invitrogen, Carlsbad, CA) according to the manufacturer’s 
instructions. 1µg RNA was reverse-transcribed with the High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems, Foster City, CA, USA). Analysis of gene 
expression was performed with TaqMan assays (Applied Biosystems, Foster City, CA, 
USA) on ABI 7300 Real Time PCR system. 18s ribosomal subunit RNA served as the 
endogenous control and gene expression was calculated by using the ⊗⊗Ct method. 
6.6.7 Protein expression: ELISA 
 
Amount of Integrin-〈V and–〈5, free and latent TGF-®, and TIMP1 (CD51:Biolegend, 
San Diego, CA; CD49e:Biolegend, San Diego, CA; LEGEND MAXTM TGF-® kits: 
Biolegend, San Diego, CA, TIMP1:Biolegend, San Diego CA) was	determined using 
ELISA kits (Biolegend; San Diego, CA) following manufacturer’s instructions. Using 
lysis buffer containing protease and phosphatase inhibitor cocktails, protein was isolated 
from hind limb and serum samples of WT and Dyw mice. The lysates were incubated 
with the capture antibody for 3 hours at room temperature followed by 5 washes with the 
wash buffer. The wells were washed 5 times for 3 minutes each and then incubated with 
detection antibodies for 2 hours at room temperature. The wells were then washed as 
described above and then incubated with Avidin-HRP conjugates. The washing step was 
repeated again as above and incubated with the substrate for 15 minutes. The reactions 
were stopped subsequently and the absorbance was recorded at 450 and 570 nm. 
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6.6.8 Statistics 
 
One- and two-way ANOVA as well as student t- tests were performed using GraphPad 
Prism 6 software. Data are presented as mean ± standard deviation. 
 
 
 
Fig. 6.2.1-Losartan attenuates alpha integrin upregulation and overexpression. A-B) 
Gene expression measured by qRT-PCR shows that Losartan induces significant 
downregulation (p<0.001, n=5, one-way ANOVA) of Integrin-〈V (A) and Integrin-〈5 (B). 
C-D) Losartan also rescues the overexpression (p<0.01, n=5, one-way ANOVA) of 
Integrin-〈V (C) and –〈5 (D), as measured by ELISA, to levels close to WT expression. 
Note, Integrin-〈5 is still significantly overexpressed (p<0.01, n=5, one-way ANOVA) in 
Losartan-treated DyW mice. * denotes significance between DyW and WT. # denotes 
significance between DyW and DyW-Losartan. *=p<0.05, **=p<0.01, ***=p<0.001, 
****=p<0.0001. Trend also applies to #. 
A	 B	
C	 D	
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Fig. 6.2.2-Losartan attenuates beta integrin dysregulation. A-E) Gene expression 
measured by qRT-PCR shows Losartan significantly downregulates integrin beta partners 
of Integrin-〈V to levels comparable to age-matched WT. * denotes significance between 
DyW and WT. # denotes significance between DyW and DyW-Losartan. *=p<0.05, 
**=p<0.01, ***=p<0.001, ****=p<0.0001. Trend also applies to #. 
A	 B	 C	
D	 E	
91 	
 
 
 
 
 
 
Fig. 6.2.3-Losartan reduces infiltrating, Integrin-〈V positive macrophages. 
Immunostaining with anti-CD51 (Integrin-〈V) as well as Mac-1 (anti-CD11b) shows that 
much of the reduction of interstitial expression of Integrin-〈V is a function of a reduction 
in infiltrating macrophages. 
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Fig. 6.2.4-Losartan reduces Integrin-〈V expression in intersitium as well as 
sarcolemma. Staining with anti-CD51 (Integrin-〈V) antibody shows a reduction in –〈V 
staining in the interstitial space as well as on the DyW sarcolemma as seen with little 
overlap with desmin in the merge panel. 
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Fig. 6.3.1-Losartan attenuates matricellular protein dysregulation. A-C) Gene 
expression measured by qRT-PCR shows Losartan induces significant downregulation 
(p<0.01, n=5, one-way ANOVA) of matricellular proteins periostin (A), osteopontin (B), 
and fibronectin (C) to levels no different from WT expression levels. * denotes 
significance between from WT. # denotes significance between DyW and DyW-Losartan. 
*=p<0.05, **=p<0.01, ***=p<0.001, ****=p<0.0001. Trend also applies to #. 
A	 B	 C	
94 	
B	 Vimentin 
8 
**** 
6 
 
 
4 
 
 
2 # ### 
0 
C	
Fo
ld
 C
ha
ng
e 
fr
om
 W
T 
Fo
ld
 c
ha
ng
e 
ov
er
 W
T 
 
 
 
 
 
 
 
 
 A	 〈-SMA 
15 
Pdgfrb 
4 
 
** 3 
10 
 
**** 
 
 
5 
 
  ## 
0 
 
2 
### 
1 
 
 
0 
 
 
 
Cdh11 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6.3.3-Losartan attenuates myofibroblast protein dysregulation. A-D) Gene 
expression measured by qRT-PCR shows significant downregulation (p<0.01, n=5, one- 
way ANOVA) in myofibroblast-related proteins including alpha-smooth muscle actin (A), 
vimentin (B), platelet derived growth factor receptor beta C), and osteoblast cadherin (D) 
in response to Losartan. * denotes significance from WT; # denotes significance between 
DyW and DyW-Losartan. *=p<0.05, **=p<0.01, ***=p<0.001, ****=p<0.0001. Trend 
also applies to #. 
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Fig. 6.3.4-Losartan attenuates myofibroblast transcription factor dysregulation. A- 
E) Gene expression measured by qRT-PCR shows significant downregulation (p<0.01, 
n=5, one-way ANOVA) of transcription factors known to drive myofibroblast 
transdifferentiation including snail (A), slug (B), twist1 (C), TCF4, and ®-catenin in 
response to Losartan. Interestingly, ®-catenin and twist gene expression is significantly 
less in Losartan-treated mice than WT mice. * denotes significance from WT; # denotes 
significance between DyW and DyW-Losartan. *=p<0.05, **=p<0.01, ***=p<0.001, 
****=p<0.0001. Trend also applies to #. 
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Fig. 6.3.2-Losartan attenuates growth factor upregulation. A-C) Gene expression 
measured by qRT-PCR shows significant downregulation (p<0.05, n=5, one-way 
ANOVA) of growth factors TGF-®1 and –®3 as well as BMP1 in response to Losartan. 
* denotes significance from WT; # denotes significance between DyW and DyW-
Losartan. 
*=p<0.05, **=p<0.01, ***=p<0.001, ****=p<0.0001. Trend also applies to #. 
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Fig. 6.4.1-Active, but not Latent TGF-®, is reduced in response to Losartan. A-B) 
Protein expression measured by ELISA shows that while both latent and active TGF-
® are overexpressed (p<0.01, n=5, one-way ANOVA) in the serum of DyW mice, only 
active TGF-® is significantly reduced (p<0.01, n=5, one-way ANOVA) in response to 
Losartan. * denotes significance from WT; # denotes significance between DyW and 
DyW-Losartan. *=p<0.05, **=p<0.01, ***=p<0.001, ****=p<0.0001. Trend also applies 
to #. 
A	 B	
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Fig. 6.4.2-Serum overexpression of TIMP1 is attenuated in response to Losartan. 
Protein expression of TIMP1 in the serum of DyW mice, measured by ELISA, is 
attenuated in response to Losartan (p<0.0001, n=5, one-way ANOVA). * denotes 
significance from WT; # denotes significance between DyW and DyW-Losartan. 
*=p<0.05, **=p<0.01, ***=p<0.001, ****=p<0.0001. Trend also applies to #. 
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Chapter 7: MRI as a biomarker for muscle size, inflammation, fibrosis, and therapy 
amelioration by Losartan 
7.1 Introduction 
 
Another important aspect to any type of therapy is a means of being able to track 
the efficacy of the drug in the clinic. In terms of muscle disease, the most meaningful 
type of tracking would be to examine muscle biopsies throughout treatment. However, 
because muscle biopsies are quite painful and for children with muscular dystrophy 
preservation of existing muscle mass is important, it would be ideal to determine non- 
invasive means with which to assess muscle health in the clinics. One such way to 
achieve this is through the use of magnetic resonance imaging (MRI). Specifically, by 
exploiting the natural MR relaxation properties, muscle size and composition can reliably 
be determined thereby allowing for precise in vivo, non-invasive assessments of muscle 
health. For example, 3D T1 weighted images can generate high-resolution measurements 
of muscle volumes and cross sectional areas while T2 weighted images allow for the 
discernment of muscle from fat, edema, and fibrotic scar tissue. For this reason, we 
sought to determine if MRI indices could detect the pathological resolution due to 
treatment with Losartan. 
7.2 MRI indices confirm Losartan does not induce postnatal weight gain in DyW mice 
 
While it has been shown numerous times that Losartan is a potent anti- 
inflammatory and anti-fibrotic agent, it has not been shown to induce significant 
postnatal total body or muscle weight gains. This is important because failure to thrive is 
a major driver of morbidity and mortality in MDC1A (and other dystrophies) and 
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therefore needs to be addressed in any therapy regimen. This study confirmed that 
Losartan does not induce total body or muscle weight gains. Both untreated and Losartan- 
treated seven-week old DyW mice weighed significantly less than age-matched WT 
littermates. There was no difference between either DyW groups (Fig. 7.2.1). The same 
trend held true for the wet weight of DyW hind limb muscles tibialis anterior (TA), 
gastrocnemius(G), soleus (S), and extensor digitorum longus (EDL). All muscles were 
roughly equivalent in weight between the treated and untreated DyW mice but both 
groups were significantly smaller than age-matched WT littermates (Fig. 7.2.1). Muscle 
cross-sectional area of TA and GS muscles supported this as both TA and GS cross 
sectional areas of treated and untreated DyW muscles were significantly smaller than WT 
mice though there was a significant difference between soleus GS of treated over 
untreated DyW mice (Fig. 7.2.1). T1 weighted MRI was used to determine muscle volume 
and showed, like the wet weights and CSA, that both anterior and posterior hind         
limb compartments were significantly smaller in both the untreated and treated DyW mice 
in comparison to WT with no difference between either DyW groups (Fig. 2.6.1). 
7.3 MR indices are sensitive to, and coincide with, amelioration of inflammation due to 
Losartan 
We next looked to determine if MRI could detect amelioration in inflammation 
and/or fibrosis following Losartan treatment. MRI images of untreated DyW mice show 
many areas of hyperintensity (indicative of inflammation) that are not seen in WT or 
Losartan-treated DyW mice. Using T2 weighted MRI of the posterior compartment of the 
hind limb, we found significantly elevated T2 values in the untreated DyW mice that were 
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reduced to levels comparable to WT in the Losartan-treated DyW mice (Fig. 7.3.1). This 
was further confirmed using highly TE sampled 1H2O sampling that showed the same 
trend. Comparing these MRI results to H&E staining of the same tissues shows that the 
results obtained via MRI, increased T2 values suggestive of inflammation that are 
reduced following Losartan treatment, is validated in that untreated DyW mice have a 
substantial number of infiltrating cells, namely macrophages, that are not found in WT 
mice and are greatly reduced in response to Losartan (Fig. 7.3.1). 
7.4 MR indices are sensitive to, and coincide with, amelioration of fibrosis due to 
Losartan 
MRI was also validated in being able to detect fibrotic resolution. Pixel-by-Pixel 
analysis of T2 weighted images shows that T2 values of untreated DyW mice were 
actually significantly lower than WT mice when restricting analyses to only areas without 
hyperintensity (Fig. 7.4.1). These low T2 values are indicative of active, collagenous, 
fibrosis (140). In response to Losartan, this same type of analysis showed that muscle T2 
values were returned to levels comparable to WT mice, suggesting a reduction of fibrosis 
in Losartan-treated mice. These results corroborate with histological and biochemical 
analyses of fibrosis. Col1a gene expression shows that DyW mice have significantly 
elevated levels of col1a transcripts as well as increased picrosirius red staining that are 
significantly reduced in response to Losartan (Fig. 7.4.1) thus validating that MRI indices 
are able to detect pathological amelioration in response to Losartan and therefore may be 
an invaluable non-invasive tool to be able to track therapy progress in the clinic. 
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7.5 Discussion 
 
In addition to serum biomarkers, the use of MRI and MR indices is a valuable too 
to track therapeutic progress in vivo. Muscle T2 has been shown to be elevated during 
inflammation (141) and decreased with fibrosis (142). In the previous study we found 
MR evidence of both decreased inflammation and fibrosis in Losartan-treated DyW 
muscle. Compared to untreated DyW mice, Losartan-treated mice had decreased total 
muscle compartment T2 values suggesting a decrease in inflammation following Losartan 
treatment. This was confirmed by a reduction in Mac-1 positive cells in treated DyW 
muscles (143). Moreover, it has been shown that fibrotic lesions — more specifically 
lesions with large amounts of collagen buildup — have a lower T2 signal intensity (144- 
146). Cardiac MRI studies in DMD subjects have reported an age related decrease in 
myocardial T2 compared to controls (147, 148) and an increase in myocardial T2 
heterogeneity (149). Similar results have been observed in animal models with diabetic 
induced cardiac fibrosis (140, 142). This was also seen in the current MRI examination of 
DyW hind limb skeletal muscle. When pixels with elevated T2 values were excluded from 
the T2 analyses, muscle T2 values in DyW mice demonstrated a significant decrease, 
suggestive of fibrotic tissue buildup (50). Interestingly, when DyW mice were treated 
with Losartan, muscle T2 values were returned to WT levels. These observations were 
validated by both histological and biochemical analyses that demonstrated Losartan- 
treated mice exhibit significantly less COL1a gene expression as well as decreased 
interstitial fibrosis as seen with Picrosirius red staining. The current study provides proof 
of concept that MRI can quantify muscle mass and composition in small animal models 
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and is able to detect changes in muscle pathology that concur with histological and 
biochemical analyses, and thus should be considered as a viable and effective non- 
invasive method of assessing therapeutic progress in preclinical studies. 
7.6 Materials and methods 
 
7.6.1 Animal breeding and care 
All animals were housed at the Laboratory Animal Care Facility – Charles River Campus 
(LACF-CRC) of Boston University on a 12:12-hr light-dark cycle. Food and water were 
provided ad libitum. All procedures were performed in accordance to the protocol 
approved by the IACUC of Boston University (protocol number 13-055). Heterozygous 
B6.129 Lama2dy-W/+ mice, carrying a targeted mutation in the Lama2 gene, were kindly 
provided by Dr. Eva Engvall (Burnham Institute, La Jolla, CA, USA). Genotyping was 
done by PCR assays on tail snips using the REDExtract-N-AmpTM kit (Simga Aldrich, St. 
Louis, MO) and mice homozygous for the mutation were used as the study animals 
(annotated DyW throughout). Losartan treatment was started at two weeks post-natal and 
continued until collection at seven weeks of age. Losartan was provided in the drinking 
water ad libitum (600mg/L, Cozaar by Merck pharmaceuticals) and supplemented with 
25g/L of sucrose to increase palatability. 
 
7.6.2 Muscle tissue collection 
 
Animals were euthanized with isofluorane (Webster Veterinary, Devens, MA, USA) 
before isolating the tibialis anterior (TA), gastrocnemius/soleus complex (GS), and 
quadriceps muscles (QD). Tissues were weighed and snap frozen in liquid nitrogen for 
RNA and protein extraction. TA/GS muscles used for histology were embedded in 
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Tissue-Tek OCT Compound (Sakura Finetek USA, Inc., Torrance, CA, USA) and frozen 
in isopentane (Sigma-Aldrich, St. Louis, MO, USA) chilled in liquid nitrogen. Serial 
transverse sections (7µm) were prepared using the Leica CM 1850 cryostat (Leica 
Microsystems, Inc.) and stored at -80 ºC (98). 
7.6.3 Histology 
 
For H&E staining, Sections were air-dried at room temperature for 5 minutes and fixed in 
chilled acetone for 5 minutes. They were then hydrated through decreasing grades of 
alcohol and stained with hematoxylin (Fisher Scientific, Fair Lawn, NJ, USA) for 1 
minute, followed by development in 1% ammonium hydroxide for 1 minute. Sections 
were subsequently stained with Ruben’s Eosin-Phloxine working Solution (Biocare 
Medical LLC) for 2 minutes. After dehydration through increasing grades of alcohol and 
xylene, sections were mounted using Cytoseal 280 (Richard Allen Scientific, Kalamazoo, 
MI, USA). For picrosirius red staining, sections were fixed with chilled acetone for 5 
minutes and then rehydrated through decreasing grades of alcohol. Rehydrated sections 
were stained with Picrosirius red solution for 15 minutes, rinsed twice in 0.5% acetic 
acid, and then dehydrated in increasing grades of alcohol and subsequently cleared in 
xylene. The sections were mounted using Cytoseal 280. 
7.6.4 Immunohistochemistry 
 
Frozen tissue sections were incubated in Acetone for 20 minutes then left to air dry for 15 
minutes. Protocol for Mouse on Mouse (M.O.M.) serial immunostaining for frozen 
sections provided by Vector Labs (Burlingame, CA) was followed using anti-CD11b 
(eBioscience, San Diego, CA) antibodies 1:200 in blocking buffer for 1 hour and washed 
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2x2 in PBS. Sections were then stained with either alexafluor goat anti mouse or goat anti 
rabbit secondary antibodies for 1 hour protected from light and washed 3x5 in PBS. 
Finally, Sections were mounted with Vectashield with DAPI (Vector Labs, Burlingame, 
CA) or 2:1 Glycerol:PBS and imaged with a Nikon DSFi1 camera head attached to a 
Nikon ECLIPSE 50i light microscope system. These images were analyzed using NIS- 
Elements Basic Research 3.0 software. Quantification of Mac-1 was accomplished by 
counting mac-1 positive cells on three separate images of the same animal and averaging 
for a total of four animals per group. 
7.6.5 Gene expression 
 
RNA from ~25 mg liquid nitrogen snap frozen pooled hind limb muscles was extracted 
with TRIzol reagent (Invitrogen, Carlsbad, CA) according to the manufacturer’s 
instructions. 1µg RNA was reverse-transcribed with the High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems, Foster City, CA, USA). Analysis of gene 
expression was performed with TaqMan assays (Applied Biosystems, Foster City, CA, 
USA) on ABI 7300 Real Time PCR system. 18s ribosomal subunit RNA served as the 
endogenous control and gene expression was calculated by using the ⊗⊗Ct method. 
7.6.6 Magnetic Resonance acquisition 
 
Magnetic resonance imaging (MRI) and spectroscopy (MRS) were performed in a 
4.7T horizontal bore magnet (Agilent). The animals were anesthetized using an 
oxygen and isoflurane mixture (3% isoflurane) and maintained under 0.5–1% 
isoflurane for the duration of the MR procedure. Respiratory rates and body 
temperatures of the mice were monitored for the entire duration of the scan. The 
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lower hind limbs of the mice were inserted up to the knee into a 2.0cm internal 
diameter, custom-built solenoid 1H coil (200 MHz). T2-weighted MR multiple slice, 
single-spin echo images were acquired with the following parameters: repetition time 
(TR): 2,000ms; echo time (TE): 14ms and 40ms; FOV: 10–20mm; slice thickness: 
1mm; acquisition matrix: 128 x 256; and two signal averages (150). Hahn spin echoes 
were implemented to avoid the contribution of stimulated echoes in the T2 
measurement. T2 was determined assuming a single exponential decay. Based on our 
previous work, we find that calculating T2 from two echoes is sufficient to 
differentiate between healthy and damaged muscle (150, 151). Signal to noise ratios 
(SNR) were 33:1 at TE = 14ms and 12:1 at TE = 40ms. Additionally, 1H 
spectroscopic relaxometry was determined from a single voxel within the posterior 
muscle compartment using Stimulated Echo Acquisition Mode (STEAM) with the 
following parameters: typical voxel size of 1.5x3.0x1.5; repetition time (TR): 
9,000ms; echo time (TE): 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 
70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, and 200ms; mixing time (TM): 
20ms; and number of phase cycled averages = 4. Furthermore, three-dimensional 
gradient echo (3D-GRE, T1 weighted) images were acquired at 4.7T with the 
following parameters: field of view: 15x15x15 mm3; matrix size: 256x192x96; 
TR/TE = 50/7ms; number of averages: 2; flip angle: 40o. 
7.6.7 Magnetic Resonance analysis 
 
Images were converted to Digital Imaging and Communication in Medicine 
(DICOM) format using a custom-made IDL code for Varian data (IDL, ITT Visual 
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Information Systems, Boulder, CO). Anterior and posterior compartments were 
outlined on axial images of the whole limb to determine the volume of individual 
compartments. Furthermore, muscle T2 values of anterior and posterior compartment 
were computed and analyzed using T2 maps, created from two echo times (TEs 14ms 
and 40ms) using OSIRIX (Version 3.9.4, Geneva, Switzerland), an open-source 
software. Muscle T2 was calculated from 6–8 middle MR images. Imaging-based T2 
was calculated using the following equation: T2  = (26ms)/ ln (SI14/SI40), where SI14 
and SI40 are the image pixel intensities at TE of 14ms and 40ms, respectively. 
Additionally, imaging T2 values of the muscle were calculated from T2 maps by 
excluding the pixels that had T2 values greater than 2 standard deviations above the 
mean muscle T2 value found in control mice (>27ms). Finally, the muscle water-only 
(1H2O) T2 data was analyzed using a custom-written software (IDL; Exelis VIS, 
Herndon, VA). Specifically, 1H2O relaxation time was derived from the decay in H2O 
signal at non-linear spaced echo times (TEs: 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 
45, 50, 55, 60, 65, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, and 200ms) 
 
using complex principal component analysis (152, 153). 1H2O T2 was determined by 
a non-linear curve fitting the decay in water signal as a function of TE using a mono- 
exponential model (154, 155) as well as using non-negative least squares (T2-NNLS) 
(156). 
7.6.8 Statistics 
 
One- and two-way ANOVA as well as student t- tests were performed using GraphPad 
Prism 6 software. Data are presented as mean ± standard deviation. 
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Fig. 7.2.1-MRI is able to detect differences (or lack thereof) in DyW muscle volume. 
A) Adult DyW mice weigh significantly less than age-matched WT littermates (p<0.01, 
one-way ANOVA). Losartan did not induce any weight gain. B-C) Untreated DyW hind 
limb muscles (Tibialis Anterior, Gastrocnemius, Soleus, Extensor Digotorum Longus) are 
significantly smaller than WT muscles in terms of weight (p<0.0001, one-way ANOVA) 
and cross-sectional area (CSA) (p<0.0001, one-way ANOVA). Losartan did not have a 
measureable effect on TA muscle weight/CSA but did result in a significant increase in 
GS CSA (p<0.05, one-way ANOVA). D) Both anterior and posterior compartments of 
DyW and Losartan-treated DyW mice are significantly smaller in terms of muscle 
volume as seen by 3D T -weighted MR analyses (p<0.01, one-way ANOVA). E) MR 
1 
images of WT, DyW, and Losartan-treated DyW mice show that DyW muscle is much 
smaller than WT and exhibit multiple areas of hyperintensity (indicated by arrows) on T2 
weighted MR images. F) Outline of anterior and posterior compartments. (* is used to 
denote significance between WT and DyW; # is used to denote significance between 
DyW and DyW Losartan-treated; * = p<0.05, ** = p<0.01, *** = p<0.001, **** = 
p<0.0001, this also applies to the other symbols). WT n=6, DyW n=8, DyW Losartan- 
treated n=4. 
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Fig. 7.3.1-MR analyses are sensitive to and coincide with inflammatory pathology 
and resolution in DyW mice. A) T 
2 
weighted MRI of the entire DyW posterior 
compartment hind limb muscles is significantly elevated compared to age-matched WT 
littermates (p<0.001, one-way ANOVA) indicative of inflammation/edema which was 
significantly reduced in response to Losartan (p<0.01, one-way ANOVA). B) DyW mice 
1 
also exhibit significantly greater localized H O T2 levels compared to WT counterparts 2 
(p<0.001, one-way ANOVA) which was also significantly lowered in response to 
Losartan treatment (p<0.01, one-way ANOVA). C-D) Histological analyses verified that 
elevated T 
2 
levels were due to muscle inflammation and edema. H&E staining shows 
extensive infiltration of inflammatory cells in DyW muscle compared to WT in both TA 
(C), and GS (B). Note: H&E images taken at 20x. (* is used to denote significance 
between WT and DyW; # is used to denote significance between DyW and Losartan- 
treated DyW; * = p<0.05, ** = p<0.01, *** = p<0.001, **** = p<0.0001, this also 
applies to the other symbols). WT n=6, DyW n=8, DyW Losartan-treated n=4. 
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Fig. 7.4.1-MR analyses are sensitive to and correlate with fibrotic pathology and 
resolution in DyW mice 
A) Pixel-by-pixel analysis of whole posterior compartment T 
2 
levels are significantly 
reduced in DyW mice compared to WT (p<0.0001, one-way ANOVA) when areas of 
hyperintensity are removed, indicative of fibrosis, specifically collagen buildup. Mice 
treated with Losartan do not exhibit this reduction of T 
2 
values following removal of 
hyperintense areas. B) qRT-PCR was used to assess COL1a gene expression. DyW mice 
exhibit significantly greater gene expression of COL1a compared to age-matched WT 
littermates (p<0.0001, one-way ANOVA), which was significantly reduced to levels not 
different than WT in response to Losartan (p<0.001, one-way ANOVA). C) Picrosirius 
red staining of posterior compartment muscle GS confirms extensive fibrosis in DyW 
mice that is rescued by Losartan treatment. Picrosirius red images taken at 20x. (* is 
used to denote significance between WT and DyW; # is used to denote significance 
between DyW and DyW Losartan-treated; ⊗ is used to denote significance between 
DyW and DyW-muscle (with removal of hyperintensive areas); & is used to denote 
significance between DyW-muscle and DyW Losartan-treated muscle; * = p<0.05, ** = 
p<0.01, *** = p<0.001, **** = p<0.0001, this also applies to the other symbols). WT 
n=6, DyW n=8, DyW Losartan-treated n=4. 
111 	
 
 
Chapter 8: Discussion and Future Perspectives 
 
8.1 Discussion 
 
While the primary genetic defects of muscular dystrophies, including MDC1A are 
well documented, it can be argued that the secondary manifestations of these diseases are 
disease drivers in their own right. Of these, the excessive deposition and hardening of 
connective tissue is a key driver of pathology. Because fibrosis disrupts the normal 
muscle architecture and disturbs contractile capacity, fibrosis lends itself to be a prime 
target for therapeutic development. The most prominent driver of fibrotic pathology is 
TGF-®-mediated signaling, which is severely dysregulated in MDC1A and an array of 
other dystrophic and neurodegenerative diseases. Also, while the downstream signaling 
consequence of TGF-® signaling, the mechanisms by which TGF-® becomes 
dysregulated in the first place during the early stages of disease remains elusive. As                       
stated before, while most TGF-®-mediated effects can be localized to Smad signaling 
intracellularly, much of the regulation of the TGF-® pathway happens in the dynamic 
environment of the extracellular matrix and therefore serves as an ideal starting point for 
understanding the mechanism by which TGF-® becomes dysregulated and through which 
other pathways it exerts its affects. 
TGF-® is secreted into the ECM non-covalently bound to its latency associated 
peptide and latent TGF-® binding proteins that tether the large latent complex to the 
surrounding ECM leaving the cytokine inactive until it is freed from this complex to bind 
to its cognate cell surface receptors to initiate signaling. This sequestering of the LLC in 
the ECM is imperative for proper regulation and function of TGF-® and defects in ECM 
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tethering have been shown to lead to a TGF-® deficient state (57-60, 64, 157). 
Conversely, recent studies have also shown that a defective or re-arranged ECM, 
associated with a fibrotic state, can lead to enhanced TGF-® signaling (56, 77, 158), as is 
seen in MDC1A-like phenotypes. The molecular adaptations both in the ECM and cell 
surface that exacerbate this phenomenon have yet to be fully understood. 
Even though one of the main binding partners of laminins are integrins, much of 
the research on integrins in muscle have been on the muscle-specific integrin 〈7®1. The 
rest of the large family of integrin proteins has largely been neglected in the muscle field 
even though integrins play many critical roles in homeostatic physiology including cell 
adhesion and signal transduction and their dysregulation has been linked to many disease 
scenarios like heart disease, cancer, and various organ fibroses. Integrin-〈V specifically 
has been intricately linked to TGF-®-mediated fibroses because of its ability to bind and 
activate TGF-® from the latent complex as well as its role in driving myofibroblast 
transdifferentiation (63-66, 72, 73, 99). 
We have shown that Integrin-〈V as well as all of its beta dimer pairs listed above 
were significantly upregulated in adult DyW mice, a time point at which fibrosis is 
widespread and still quite active. We also found that matricellular proteins, known to 
activate Integrin-〈V to facilitate TGF-® release from the latent complex were also 
upregulated. We determined that Integrin-〈V was not only expressed in diseased muscle 
but also localized to the sarcolemma of DyW myofibers, a phenotype not found in WT 
muscle and a pathological phenomenon that was never previously reported. We also 
found compelling evidence of myofibroblast transdifferentitation (myofibrogenesis) in 
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adult DyW mice including significant upregulation of marker proteins and transcription 
factors involved in myofibrogenesis. Further, these markers were also upregulated in 
developing DyW mice. These findings could be extremely valuable in understanding how 
a dysregulated and stiffened myomatrix impacts early myogenesis, particularly in the 
context of congenital muscular dystrophy. Importantly, we also showed that these 
dysregulated pathways could be reversed by anti-fibrotic therapy, such as with Losartan. 
Overall, these results point to Integrin-〈V and myofibroblast differentiation 
playing possibly etiological roles in driving DyW pathology based on the very early status 
of their dysregulation. While further experiments are needed to determine the underlying 
mechanisms for how these pathways are becoming dysregulated and their           
(potential) relation back to the genetic deficiencies of DyW mice, we nevertheless believe 
that these pathways could serve as potent targets for future therapy. On a different note, 
because of the severity of MDC1A and its presentation in such young children, non- 
invasive biomarkers for diagnosis and prognosis are critical to track disease state in the 
clinic. While the methods need further validation, the preliminary elucidation of serum 
biomarkers as well as MRI could serve as critical parameters in clinical trial designs for 
patient populations in dire need. Further, because of the commonality of secondary 
manifestations, the results of this work could be extrapolated to an array of other fibrotic, 
neurodegenerative diseases. 
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8.2 Future perspectives 
 
8.2.1 Origins of myofibroblasts, potentially myoblasts? 
 
One key area of investigation that was not covered in this study is the origin of 
the cells that are undergoing myofibroblast transdifferentiation. It has been shown that 
multiple different cell types have the ability to undergo transdifferentiation to 
myofibroblasts under the right conditions including fibroblasts, endothelial cells, 
fibrocytes, pericytes, and smooth muscle cells (76, 101). Common to many of these 
transdifferentiation procedures is the appearance of excessive TGF-® signaling, 
monocyte chemoattractant protein-1 (MCP-1), and EDA-FN in the ECM. All of these 
proteins are found to be upregulated in these dystrophic muscles again suggesting that the 
environment for myofibroblast transdifferentiation is optimal and thus may be playing a 
large role in exacerbating fibrotic pathology in the MDC1A phenotype. 
Most interesting however, is the possibility that myoblasts could be undergoing 
transdifferentiation to myofibroblasts, which could be playing a huge role in the complete 
lack of satellite cell-driven postnatal growth in DyW muscles. Further experiments could 
be devised to test this premise including utilizing the Pax7/Cre-Rosa/YFP mouse which 
will express YFP in any cell that expresses Pax7 i.e. for our purposes, satellite cells (159). 
This can be used to track satellite cells and determine if they express myofibroblast 
markers during the development of fibrosis in DyW mice. This could be further 
confirmed using the Cre-Lox/®-galactosidase system to determine if myofibers are 
actually dedifferentiating to become myofibroblasts as well (160). We would expect to 
see multiple Pax7- and/or ®-gal-positive cells co-expressing myofibroblast markers. This 
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result would confirm that myoblasts and myofibers, respectively, are transdifferentiating 
to myofibroblasts thereby exacerbating dystrophic pathology. While all these are 
extremely intriguing experiments, they were outside the scope of this thesis but 
nonetheless warrant consideration for further experimentation. 
8.2.2 What about the matrix itself? 
 
A further consequence of fibrosis and signaling through Integrin-〈V is the 
stiffening of the matrix. This stiffening is inherently detrimental to muscle function as 
well as myogenesis. In addition to the already discussed negative affects of the 
dysregulated chemical structure of the matrix, a dysregulated structural matrix has also 
been shown to be detrimental (158). Increased matrix stiffness leads to defective muscle 
cell differentiation (161). Experiments could be devised to determine if the matrix 
stiffness directly induces transdifferentiation of myoblasts and if blocking Integrin-〈V 
signaling can reduce the propensity of myoblasts to undergo this transdifferentiation. This 
could be done using polyacrylamide gels of various stiffness and comparing expression of 
myofibrogenesis-related proteins both in the presence and absence of an Integrin-〈V 
inhibitor like CWHM-12. 
More advanced techniques could be used to preserve the interplay of both the 
chemical and structural composition of the fibrotic matrix on transdifferentiation by 
plating WT muscle cells on decellularized DyW muscle. Gillies et al. (2011) have shown 
that using the actin depolymerizer latrunculin b followed by a few rounds of osmotic 
shock can decellularize muscle tissue while preserving the mechanical characteristics and 
is viable for cell implantation (162). This scaffold could be used to determine if the total 
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interplay of the matrix is enough to induce WT cells to undergo transdifferentiation and if 
integrin-〈V is necessary for this process. 
8.2.3 Bringing it back to Laminin 
 
While much of this work has dealt with elucidating downstream consequences of 
Laminin-deficiency, there has not been a direct link between integrin dysregulation 
and/or myofibroblast transdifferentiation back to the Laminin. Preliminary experiments 
with siRNA show that silencing Laminin-〈2 leads to a significant increase in Integrin- 〈V 
transcription. Therefore, it is possible that loss of Laminin, and secondarily a decrease in 
〈7®1-integrin expression, leads to a compensatory increase in other integrins like 
Integrin-〈V. It is also possible that loss of a protein critical to basement membrane 
formation and sarcolemma protein localization leads to dysregulated matrix and therefore 
different sets of proteins necessary to adhere and interact with the dysregulated matrix. 
Further experiments could be devised that utilize siRNA to silence Laminin expression 
and determine if Laminin-deficiency results in a dysregulated matrix deposition of 
muscle cells which in turn induces compensatory upregulation of distinct membrane 
proteins. These experiments would shed new light on the earliest defects that can be 
ascribed directly to Laminin-deficiency and not a secondary manifestation common to 
many dystrophies. 
8.2.4 How did Integrin-〈V get on the DyW myofiber? 
 
Perhaps the most intriguing result of this study is the finding that Integrin-〈V is 
expressed on DyW myofibers, a possible pathological adaptation to fibrotic pathology 
that was not previously described. While it is known that Integrin-〈V is expressed during 
117 	
 
 
primary myogenesis, its expression completely goes away after the emergence of muscle- 
specific 〈7®1-integrin (103). Therefore, the finding that it is expressed in adult DyW 
mice is a novel shift in adult muscle phenotype and a potential adaptation to fibrotic 
pathology that require further probing to understand the molecular mechanisms behind 
this phenomenon. One potential explanation that was previously stated, is the loss of 
Laminin patterning and subsequent basement membrane formation and sarcolemmal 
protein localization could induce compensatory upregulation. It is also possible that 
chronic TGF-® signaling and different transcriptional profiles and epigenetic 
modifications from normal, postnatal activity in skeletal muscle could pattern the genome 
to be newly susceptible to Integrin-〈V expression (163). Preliminary evidence shows that 
at two weeks postnatal, Integrin-〈V is restricted to the interstitium. Further, myoblasts 
isolated from 7-week DyW mice do not express Integrin-〈V (data not shown) as do the 
myofibers. Lastly, this phenotypic change coincides with the results elucidated in the mdx 
model showing that chronic TGF-® signaling dysregulation leads to a loss of       
myogenic identity and shift toward a mesenchymal phenotype (122), a population of cells 
known to express Integrin-〈V. Further experiments should be devised to determine the 
relevant modifications that occur to allow Integrin-〈V expression and membrane 
localization which could include but are not limited to assessing the epigenetics of the 
Integrin-〈V gene in 7-week DyW vs. WT mice to determine if changes in chromatin 
packing could be playing a role in its expression, ChIP-seq analyses to determine the 
relevant transcription factors playing a role in skeletal muscle cell transcription of 
Integrin-〈V, and Integrin-〈7®1 silencing experiments to determine if the loss of muscle- 
118 	
 
 
specific integrins is directly related to the expression of Integrin-〈V on muscle cells. 
Determining the mechanism of this pathological adaptation is another critical step to 
determine how a loss of Laminin influences the muscle microenvironment and offers 
another potential set of therapeutic targets. 
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